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httpABSTRACT
Currently, testing for immunoglobulin E (IgE) sensitization is the cornerstone of diagnostic evalu-
ation in suspected allergic conditions. This review provides a thorough and updated critical
appraisal of the most frequently used diagnostic tests, both in vivo and in vitro. It discusses skin
tests, challenges, and serological and cellular in vitro tests, and provides an overview of in-
dications, advantages and disadvantages of each in conditions such as respiratory, food, venom,
drug, and occupational allergy. Skin prick testing remains the first line approach in most instances;
the added value of serum specific IgE to whole allergen extracts or components, as well as the role
of basophil activation tests, is evaluated. Unproven, non-validated, diagnostic tests are also dis-
cussed. Throughout the review, the reader must bear in mind the relevance of differentiating
between sensitization and allergy; the latter entails not only allergic sensitization, but also clinically
relevant symptoms triggered by the culprit allergen.
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http://doi.org/10.1016/j.waojou.2019.100080KEY STATEMENTS immunotherapy (AIT) are required to achieve Clinical suspicion of allergic sensitization is
confirmed by demonstrating the presence of
allergen-specific IgE antibodies in vivo (skin
tests) or in vitro.
 Confirmation of allergen sensitization and the
identification of causal allergens are essential for
optimizing the management of allergic
conditions.
 Skin prick testing (SPT) is the most frequently
used method for the detection of IgE antibodies,
due to its rapidity, simplicity and low cost. Skin
prick tests and other skin test results must be
interpreted by a clinician with adequate knowl-
edge of medical history, clinical findings, and
relevant type I allergens (including environ-
mental, food, animal, insect, fungal, and drug
allergens). Skin tests should include the relevant
allergens in the given geographical area and
ideally carried out only using standardized
allergenic extracts.
 In vitro tests, including molecular based allergy
diagnostics, using either in single-plex and in
multi-plexed strategies and other more func-
tional tests, such as Basophil Activation Tests
allow to better define the IgE profile of the pa-
tient. This approach is in line with the Precision
Medicine statements.INTRODUCTION
Allergic diseases are amongst the most preva-
lent diseases worldwide and the burden of these
diseases continues to increase. An accurate diag-
nosis coupled with optimal therapy requires the
use of appropriate tests to confirm the allergen
sensitization and detailed information about
exposure to the putative allergen. Skin tests,
especially SPT, represent the most reliable and
cost-effective tool for the diagnosis and manage-
ment of IgE-mediated diseases,. They demonstrate
a good correlation with outcomes of nasal,
conjunctival, dermal, oral and bronchial
challenges.
Once the diagnosis has been established, and
the relevant allergens have been identified, spe-
cific treatments, including medications, environ-
mental control measures and/or allergenoptimal, long-term outcomes. Allergy diagnosis,
hence, may be categorized as precision medicine.
Several types of skin tests are used in allergy
diagnostics:
1) Skin Prick Test (SPT): This represents the first
level of approach for the diagnosis of type I,
immediate, IgE-mediated allergy. It is safe, has
high sensitivity and good specificity when per-
formed and interpreted correctly; a specific
variant of type I skin tests is prick-to-prick testing
(PPT) with native allergens.
2) Intradermal Test (IDT): This can be used to
evaluate both immediate IgE-mediated allergy
and delayed-type hypersensitivity, according to
the time of read-out. It has increased sensitivity
and decreased specificity compared to SPT.
3) Patch test: This is used for delayed type, cell-
mediated, hypersensitivity reactions. It has no
relevance for IgE-mediated allergy and thus will
not be further examined in the present
document.
The in vitro diagnosis of IgE-mediated allergic
diseases is useful in the identification of the caus-
ative allergen(s) and usually involves different lab-
oratory procedures. In particular:
1) The total IgE assay which is nonspecific and
provides only gross information.
2) Serum specific IgE assays against allergen
sources/molecules are the most commonly
used in vitro diagnostic approach. They can be
performed by a singleplexed or multiplexed
strategy.
3) The Basophil Activation Test (BAT) which is
quite specific, but complex to perform, and
therefore limited to selected situations.
The first part of the present manuscript focuses
on skin testing in the diagnosis of IgE-mediated
allergy and is intended for all practitioners. There
have been criticisms that the procedure is often
left to technicians and nurses with limited expertise
and poor attention towards quality control and
methodological standardization.1 Surveys have
highlighted the variability of the technical
methodology2–4 and also the interpretation and
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practitioners. In the present document,
recommendations for its clinical use, technical
aspects, reporting, and interpretation of the
results have been revised and updated. The
second part deals with the in vitro techniques
(serum IgE assays and cell-based assays), discus-
sing characteristics, performance and indications
for the various approaches. The third part includes
allergen provocation testing. A final part is dedi-
cated to special situations, where the confirmation
or exclusion of an IgE-mediated disease mecha-
nism is required (allergies to foods, drugs, insect
venoms or occupational agents).
IN VIVO DIAGNOSIS: SKIN TESTS
Skin prick test
General information
The credit for the first skin testing devices goes
to Charles H. Blackley, who in 1865 abraded a
quarter-inch area of skin with a lancet, producing a
dermographic reaction. In 1924, Lewis and Grant
first described the skin prick test (SPT) method.
SPT is the simplest in vivo method to assess the
presence of IgE sensitization in humans. When a
specific allergen is introduced through a lancet
into the skin of allergic individuals, dermal mast
cells begin to degranulate mainly due to the cross-
linking of allergen-specific IgE bound to their
membrane receptors. Degranulation leads to the
immediate release of histamine and other media-
tors, inducing a cutaneous response, clinically
characterized by a wheal (sometimes with pseu-
dopods) and surrounding erythema (flare) that can
be measured in order to assess the degree of
cutaneous sensitivity. Thus SPT represents a sur-
rogate indicator of systemic allergic sensitization
(i.e., nose, lungs, eyes, gut) through the presence
of cutaneous reactivity to specific allergens.
When should skin prick tests be performed?
The diagnosis of allergy requires an appropriate
medical history and physical examination. If the
clinical information suggests type I (immediate-
type) allergy, SPTs are indicated to detect the
presence of specific IgE to relevant causative al-
lergens: inhalant, food, hymenoptera venoms,
drugs and, in some cases, occupational allergens.
Type I hypersensitivity (immediate) is suspectedclinically when reactions occur within 30–120 mi-
nutes of exposure.
In general, clinical conditions where SPT is
indicated are the following:
 Asthma;
 Rhinitis/rhinosinusitis/rhino-conjunctivitis/
conjunctivitis;
 Eczema/atopic dermatitis (in the setting of
selectively high clinical suspicion for underlying
presence of IgE hypersensitivity to specific
allergens);
 Suspected food allergy (oral allergy syndrome,
anaphylaxis/acute onset or exacerbation of urti-
caria or eczema that is temporally correlated
with food ingestion);
 Suspected drug allergy;
 Hymenoptera venom allergy (systemic reactions
immediately following insect sting);
 Suspected occupational disease or exposure to
selected potential allergens;
 Chronic urticaria in rare selected cases which
strongly suggest an allergen as potential trigger/
aggravating factor;
 Less common disorders, such as eosinophilic
esophagitis, eosinophilic gastroenteritis or
allergic bronchopulmonary aspergillosis, where
IgE sensitization is one of the characteristics of its
pathogenesis. However, there is controversy
regarding the utility of SPT for these illnesses.
On the contrary, SPT is not routinely indicated in
the following instances in the absence of other
existing features of allergic disease:
 Suspected food intolerance (e.g., irritable bowel
syndrome, etc.);
 Chronic urticaria in the absence of allergic fea-
tures in the history;
 Desire to lose weight (according to non-
conventional approaches, obesity may be due
to food intolerance, but no supporting scientific
data have been reported in the literature);
 Non-specific food-associated symptoms to food
additives/preservatives/colorants;
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immunotherapy (but may be supportive in Hy-
menoptera venom immunotherapy);
 Non-specific respiratory symptoms to irritants
(i.e., smoke, perfumes, detergents, chemicals
and other strong odors);
 Screening for allergic sensitization patterns in
the absence of clinical symptoms (i.e., family
history of allergy);
 Non-specific cutaneous rashes in the absence of
atopic features or other allergic symptoms;
migraine, except for the indication of specific
hypersensitivity to hormones. However, strong
scientific data are still missing.
 Chronic fatigue syndrome.
SPTs with great fidelity provide an objective and
reliable confirmation of allergic sensitization.
However, the clinical relevance of IgE-mediated
sensitizations should always be carefully consid-
ered since, sometimes, positive SPTs do not
directly imply allergic manifestations. A correct
diagnosis of type I allergic conditions is quite
important in order to choose proper avoidance
measures and to prescribe allergen immuno-
therapy, when needed. When indicated, SPTs are
convenient, simple, biologically relevant, repro-
ducible, time- and cost-effective, and highly sen-
sitive. They can be performed in parallel to serum
specific IgE (sIgE) detection, and in specific cases,
accompanied by other allergen challenge tests to
evaluate the clinical relevance of the allergic sen-
sitizations. SPTs assess the presence of allergen
specific IgE bound to mast cells in the dermis.
These mast cells can bind individual allergen
specific IgE molecules for over one year. Allergen
specific IgE blood tests measure of the presence of Stop H1-antihistamines the required number of da
listed below (most antihistamines 4–5 days, ideally
 Stop H2-antihistamines for 24 hours before perfor
 Stop anti-depressants with H1-antihistamine activity
 It is not necessary to stop leukotriene antagonists.
 If possible, avoid use of high potency topical stero
where skin tests are to be applied.
Table 1. Recommendations on medications that possibly interfere withthis antibody. These tests may be viewed as
complementary.
The clinician who performs/interprets the SPT and
the setting
A clinician with adequate knowledge of the
important, relevant suspected allergens, based
upon the patient's history and the geographic
area, should decide which specific allergens are
tested and interpret the clinical significance of the
test results. SPT must be performed under medical
supervision, with emergency equipment available
for the treatment of anaphylaxis. The risk of sys-
temic reactions in clinically stable patients is
extremely low when using standardized respiratory
allergen extracts.
Skin tests reporting form
As for any medical procedure, it is essential that
proper documentation be recorded. An ideal skin
testing form should list the following information:
 name and date of birth of the patient;
 date of the skin test;
 name, address, and telephone number of the
responsible physician;
 region tested (e.g., back, forearm);
 name of technician/nurse/doctor/health profes-
sional trainee who performed the test;
 type of device used;
 negative and positive controls (type and con-
centrations), with the respective results;
 name of each allergen tested as reported on the
commercial bottle (with genus and species
identifier), followed by local/common names,
concentration, and manufacturer;ys according to the characteristics of the drugs
7 days) before performing skin tests (Table 3).
ming skin tests (Table 3).
1 week before test (ask prescriber if it is possible).
ids, optimally three weeks before SPT, in places
SPT
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dilution should be recorded;
 size of the resulting wheal and flare for each
allergen after pricking;
 time point of reading the result, usually 15–
20 minutes;
 optional: check box for pre-medications poten-
tially interfering with the result before starting.
Records of extract source, lot number as well as
expiration date may be kept separately.
Drugs possibly interfering with skin prick tests
Before testing, the clinician should verify that the
patient has not been taking medications that might
interfere with testing. According to the guideline
recommendations of the Joint Task Force on
Practice Parameters of the American Academy of
Allergy Asthma and Immunology (AAAAI), the
American College of Allergy Asthma and Immu-
nology (ACAAI) and the European Academy of
Allergy and Immunology (EAACI), certain medica-
tions should be discontinued to avoid suppressive
effects on the immediate wheal and flare skin test
response (Tables 1 and 2).
 This effect is attributed to a combination of a
decrease in mast cell recruitment and an in-
crease of mast cell apoptosis.
Allergen extracts for SPT
The number of skin tests and the selection of
allergens for skin testing should be determined
based on specific clinical history, allergen expo-
sure pattern (seasonal versus perennial, or spo-
radic), distribution of allergenic sources in the local
environment as well as living conditions, occupa-
tion, hobbies, or recreational activities.7
Patient populations tend to be highly mobile,
hence exposure to different allergens at different
places may occur.
Allergenic extracts consist of mixtures of aller-
genic (proteins, glycoproteins, polysaccharides)
and non-allergenic components (lipids, salts, pig-
ments, metabolites) derived from the allergenic
source. Crude extracts thus usually contain both
genuine sensitizers and cross-reactive proteins.
Allergens in general are mainly proteins or glyco-
proteins, but carbohydrates or other low-molecular weight haptenic chemicals, when trans-
formed to complete antigens, can also induce
allergic sensitization.
Allergen extracts are usually obtained from
natural sources by aqueous extraction. Their
composition and biologic properties may be
influenced by the quality and purity of the source
material, the methods of extraction and process-
ing, as well as the storage conditions. Extracts
should not contain more than one allergenic
source (mixes can be used if containing sources
from a homogeneous taxonomic family) and
should not contain interfering preservatives such
as thiomersal.
Diagnostic extracts made of recombinant or
highly purified allergenic proteins are available in
some countries where they are approved for al-
lergy diagnostics. Recombinant and natural
allergen preparations have been evaluated and
compared. In general, skin testing with synthesized
allergens is highly specific and avoids the creation
of false positives by the elimination of cross-
reactive allergens. However, the precise role of
recombinant allergens as an in vivo diagnostic tool
remains to be fully determined.
Allergenic extracts used for diagnostics should
ideally be standardized, both in vivo and in vitro
(meaning that manufacturers should quantify the
presence of major allergens in their allergenic ex-
tracts). Standardization facilitates the comparison
of extracts from different manufacturers, lot to lot
variability, and the reliability and reproducibility of
test results.8
Current standardization is crucial particularly in
European countries, where strict regulatory rules
have led sometimes to a problematic and costly
registration of some products.9 Allergenic extracts
should also be cost effective.
Stability and potency of the allergen test ex-
tracts are also important issues. Since allergen
extract potency deteriorates with time, accelerated
by dilution and higher temperatures, allergen skin
test extracts are usually preserved with 50% glyc-
erin. All extracts should be stored in a refrigeration
unit at 2–8 C to improve stability.
For diagnostic use, both standardized and non-
standardized products are commercially available
Drugs Generic drug
Day(s) suppressed
Despite the intervals indicated, the higher
limit of the interval is recommended
H1-antihistamines
First generation Chlorpheniramine 2–6
Clemastine 5–10
Cyproheptadine 9–11
Dexchlorpheniramine 4
Diphenhydramine 2–5
Hydroxyzine 5–8
Promethazine 3–5
Tripelennamine 3–7
Second generation Azelastine nasal 3–10
Ebastine 3–10
Cetirizine 3–10
Fexofenadine 2
Loratadine 7–10
Desloratadine 3–10
Levocetirizine 3–10
Bilastine 4–5
Levocabastine nasal Do not suppress skin tests
Levocabastine ophthalmic Do not suppress skin tests
Rupatadine 3–7
Tricyclic antidepressants
and tranquilizers
Desipramine 2
Imipramine >10
Doxepin 6–11
Doxepin topical 11
H2-antagonists Ranitidine 1
Anti-IgE monoclonal
antibody
Omalizumab Prick tests can be performed after 6 weeks but
false negative results can occur up to one
year226
Cysteinyl leukotriene
receptor antagonists
Montelukast Does not suppress skin tests
Zafirlukast Does not suppress skin tests
Short term oral
corticosteroids
30 mg of prednisone daily
for 1 week
Do not suppress skin tests
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Drugs Generic drug
Day(s) suppressed
Despite the intervals indicated, the higher
limit of the interval is recommended
Long term and relatively
high dose corticosteroids
>20 mg/d Possible suppression of immediate skin test
reactions
Potent topical
corticosteroids**
>3 weeks Suppress immediate skin test over areas where
they have been applied
Local anesthetic EMLA (Eutectic Mixture of
Local Anesthetic) cream
1 h before test suppression (only suppresses
erythema)
Table 2. (Continued) Suppressant effects of drugs on immediate skin testing * NB: Where this article reports in fractions of days, the total has been
rounded up. Maximum days would apply to most patients, but there may be exceptions where suppression could last longer. Adapted from Bernstein IL, Li JT,
Bernstein DI et al. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol 2008; 100 (Suppl 3):S1–S148.227
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examples are provided in Table 3).
Number of skin tests
A pan-European study of skin tests, supported
by the Global Allergy and Asthma European
Network (GA2LEN), showed that, for respiratory/
conjunctival allergies, it is not necessary to include
a large number of allergen extracts for skin tests, at
least in Europe. The total number of allergens
tested depends, as mentioned above, on the local
exposure framework. The suggested panel for
respiratory allergy includes 18 allergens, as fol-
lows: alder (Alnus incana), birch (Betula alba/ver-
rucosa), cypress (Cupressus sempervirens/
arizonica), hazel (Corylus avellana), plane (Platanus
vulgaris), grass mix (including Poa pratensis, Dac-
tilis glomerata, Lolium perenne, Phleum pratense,
Festuca pratensis, Helictotrichon pratense), olive
(Olea europea), mugwort (Artemisia vulgaris),
ragweed (Ambrosia artemisiifolia), Alternaria
alternata (tenuis), Cladosporium herbarum, Asper-
gillus fumigatus, Parietaria, cat (Felis domesticus),
dog (Canis familiaris), dust mite (Dermatopha-
goides pteronyssinus/farinae), and cockroach
(Blatella germanica).10 In tropical countries, testing
with Blomia tropicalis is recommended.11 The
number of tests performed should be much
lower when testing infants.
Information regarding cross-reactivity among
allergens is important when interpreting results.
Cross-reactivity describes the phenomenon
whereby an immediate type skin reaction by a
particular allergen (genuine sensitizer) can also be
elicited by other similar allergens and is explainedby IgE cross-reactivity to homologous (cross-reac-
tive) allergens. Cross-reactivity of pollens is
frequent among taxonomically related plants or in
the case of highly conserved proteins across
different species (Table 4).
Generally, fewer tests to suspected allergens are
required in infants and very young children (<2
years of age) because children are not likely to be
sensitized to as many allergens as older children
and adults. In toddlers, allergic sensitization re-
flects intense and/or prolonged exposure to aller-
gens encountered early in life, such as foods,
house dust mites, indoor molds, and animal
dander rather than pollens.12
Relatively few foods account for most IgE-
mediated allergic reactions in both children and
adults. The more common food allergens in infants
and young children are: cow's milk, hen's egg,
peanuts, tree nuts, soybeans, and wheat, whereas
the adult counterparts are peanuts, tree nuts, fish,
crustaceans, mollusks, fruits, and vegetables.
However, this generalization does not preclude the
possibility that larger numbers of tests may be
required, if multiple or hidden food allergies are
suspected; this must be weighed against a high
false positive response rate. PPT (Prick-Prick
testing) whereby a fresh food sample is pricked
followed by immediate pricking of the skin in
suspected vegetable and fruit IgE-mediated re-
actions can provide greater sensitivity. Occupa-
tionally related allergy (e.g., latex, rodents, flour,
food inhalants, etc.) is a special clinical condition
for which a limited number of reliable skin test
reagents are available.
Allergen product Skin prick test concentration Intradermal test concentration
Standardized short ragweed 1:20 w/v 1:1000 w/v
Standardized cat hair 10,000 BAU/mL 200 BAU/mL
Standardized grass pollens 10,000–100,000 BAU/mL 200 BAU/mL
Standardized Hymenoptera venoms 100 mg protein/mL 0.1–1 mg protein/mL
Standardized mites 10,000 AU/mL 200 AU/mL
Non standardized allergens 1:40–1:20 w/v 1:1000 w/v
Table 3. Examples of skin test concentrations of standardized and non-standardized allergens. Adapted from Dolen WK, MD. Immunology and
Allergy Clinics of North America. Volume 21, number 2 May 2001. Saunders. Selection of allergen products for skin testing by Robert E. Esch, PhD.228
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Available devices for skin prick testing
There are a variety of devices for performing
skin tests throughout the world, developed in
an attempt to improve reproducibility of the
skin prick test method. Devices used generally
are designed with a sharp point (0.9 or 1 mm)
and a shoulder to prevent excessive penetration
into the dermis. The most popular instruments
are the Morrow Brown standardized needle, the
“Greer Pick” (DKL), the Stallerpoint, and the
Phazet. Puncture tests can also be performed
with a bifurcated smallpox vaccination needle, a
23G intravenous needle or with other devices.
Several plastic devices with multiple heads
(“multi-headed” skin test devices) have also been
developed to apply several skin tests at the same
time, which may limit technician time, and in-
crease efficiency.
The inter-device wheal size variability is highly
significant (Table 6). Potential causes of this
variability include depth of penetration into the
skin, amount of antigen entering the skin, angle
of penetration, and skill of the investigator. It is
imperative that the allergist/immunologist
understands the characteristics of the device
chosen (Table 7).
Skin prick test technique
SPT must be performed on normal skin. SPT are
usually applied, for practical reasons on the volar
surface of the forearm; but other sites are equally
effective. The antecubital fossa is the most reactive
portion of the arm, whereas the wrist is the lessreactive. The ulnar side of the arm is more reactive
than the radial area. In infants, the back is the
preferred site for SPT. It is recommended that tests
should not be placed within 5 cm of the wrist and
3 cm of the antecubital fossa. Skin tests should not
be performed on skin sites with active dermatitis,
severe dermographism and tattoos. Ageing of the
skin, and sun damage will affect the skin's reac-
tivity. The location of each allergenic drop can be
marked with a pen or a test grid. The allergenic
solution placed on the skin should be immediately
pricked.
The selected test site is cleansed and dis-
infected with alcohol and allowed to dry. After
marking the skin sites to place the extract drops
with numbers, codes, or using a template, the
allergen extracts are applied to the skin, depos-
iting a drop of allergen extract on the skin of the
forearm of the patient. The puncture device is
passed through the drop at a 45–60 angle to the
skin, achieving penetration of small amounts of
allergen extract just below the epidermis. This is
called the skin prick test (alternatively, the skin
device may be passed through the drop at a 90
angle to the skin with gentle pressure for 1 second,
this is called a puncture test). The drops must be
placed 2 cm or more apart each other to avoid
mixing or overlapping and therefore false-positive
reactions. If mast cells are sensitized with specific
IgE in the patient's tissue, the penetration of the
allergen causes the release of histamine, resulting
in a wheal and flare response.
Because of inter-patient variability in cutaneous
reactivity, it is necessary to include negative and
positive controls at the same time as allergen tests
in every skin test evaluation. Positive control
Cross-reacting
groups Representative genera
a
Grass
Pollens
Pooideae Poa (bluegrass), Bromus (brome), Dactylis (orchard), Festuca (fescue),
Lolium (perennial rye), Agrostis (redtop), Anthoxanthum (sweet vernal),
Avena (cultivated oat), Holcus (velvet), Phalaris (reed canary), Phleum
(timothy), Agropyron (quack), Elymus (wild rye), Secal e (cultivated rye),
Triticum (cultivated wheat)
Chloridoideae Cynodon (Bermuda), Bouteloua (blue grama, mosquito Grass), Distichlis
(salt)
Panicoideae Paspalum (Bahia), Sorghum (Johnson), Panicum (Para grass), Zea (corn)
Tree
Pollens
Aceraceae Acer (maples and box elder)
Betulaceae Alnus (alder), Betula (birches), Corylus (hazelnut)
Cupressaceae Cupressus (cypress), Juniperus (junipers and cedars), Taxodium (bald-
cypress), Cryptomeria (Japanese cedar)
Fabaceae Acacia (mimosa), Robinia (locust), Prosopis (mesquite tree)
Fagaceae Quercus (oaks), Fagus (beech)
Juglandaceae Carya (hickory and pecan), Juglans (walnut)
Moraceae Morus (mulberry), Broussonetia (paper mulberry)
Oleaceae Olea (olive), Fraxinus (ash), Ligustrum (privet)
Pinaceae Pinus (pines)
Platanaceae Platanus (sycamore)
Salicaceae Populus (cottonwood and poplars), Salix (willows)
Ulmaceae Ulmus (elms)
Weed
Pollens
Chenopodiaceae Atriplex (scales and saltbush), Chenopodium (lamb's quarter), Salsola
(Russian thistle), Kochia (firebush), Allenrolfea (iodine bush)
Asteraceae:
Artemisia
Artemisia (mugworts, wormwood, sages)
Asteraceae:
Ambrosia
Ambrosia (ragweeds), Xanthium (cocklebur), Iva (poverty weed hemp)
Amaranthaceae Amaranthus (careless weed, pigweeds), Acnida (Western water hemp)
Plantaginaceae Plantago (plantain)
Polygonaceae Rumex (dock and sorrel)
Urticaceae Parietaria
Table 4. Cross-reacting pollen allergen groups. a. Representative genera are members of the same botanical family or subfamily. Manufacturers
currently offer allergen products derived from one or more species of each listed genus
Volume 13, No. 2, February 2020 9solutions (histamine phosphate, used at a con-
centration of 5.43 mmol/L or 2.7 mg/mL, equiva-
lent to 1 mg/mL of histamine base) are used to
detect suppression by medications or disease,
detect the exceptional patients who are poorlyreactive to histamine, and determine variations in
technician performance and/or the potency of the
testing reagent. Histamine dihydrochloride is
commercially available and has been approved for
the use for in vivo testing in Japan.
 Include skin test allergens relevant to the specific geographical region.
 Standardized allergen products should be used for skin testing whenever possible.
 Clinical history should guide skin testing, as there is a potential for false positive responses.
 More allergens may need to be assessed in areas with greater biodiversity and warmer climates.
 Limit the number of allergen used in skin testing, taking into account cross-reactions and eliminating
allergens irrelevant in the exposure area.
 Include a positive (histamine) and a negative (buffer) controls.
Table 5. Recommendations for SPT
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human serum albumin–saline) will also detect
traumatic reactivity induced by the skin test device
(with a wheal which may approach a diameter of
3 mm with some devices) and/or the technique of
the tester or the presence of dermographism.
Some of the most common errors in skin prick
testing are listed in Table 8.
Measurement and interpretation of skin prick test
Skin tests should be read at the peak of their
reaction and in a standardized manner. Whatever
the method, the immediate skin test induces a
response that reaches a peak in 8–10 minutes for
histamine and 15–20 minutes for allergens. The
reading and evaluation of skin tests using an
arbitrary scale of 0–4 þ is not recommended un-
less the specific criteria for the scale are defined on
the skin test form.The least variable method, which
is both objective and reproducible, occurs when
the wheal's size is measured in millimeters (mm)
with a ruler. The size of the reaction may be
recorded as a mean wheal diameter, D þ d/2 (with
D indicating the largest diameter of the wheal and
d indicating the largest diameter orthogonal to D).
Other Authors suggests (D þ d)/2. Pseudopods
are not included in the measurement, but can be
marked separately. A prick/puncture test with a
response of at least 3-mm diameter in wheal more Avoid devices or techniques that produce a negati
the possibility of producing a false positive reactio
 Ideally use the same device to improve reliability,
 Strictly avoid deep punctures associated with blee
Table 6. Recommendations on SPT devicesthan simultaneously performed diluent control is
required as proof of the presence of cutaneous
hypersensitivity, indicative of the presence of spe-
cific IgE.
The presence of allergic sensitization (a positive
SPT with no correlative allergic disease) is a com-
mon finding, occurring in 8–30% of the population
when using a local standard panel of aero-
allergens. Interestingly, a prospective study13
reported that 60% of skin prick test positive
(wheal > 4 mm) asymptomatic subjects
developed clinical allergy, thus, the presence of
positive SPT in asymptomatic subjects may
predict the subsequent development of allergic
symptoms.
False-positive tests may be provoked by impu-
rities, contaminants, and non-specific mast cell
secretagogues in the extract, as well as dermog-
raphism. Devices used and techniques applied
should also be considered when comparing mea-
surements to the negative control.
The most common cause of false-negative tests
is the ingestion of a drug that inhibits the effect of
histamine. In addition, skin reactivity is decreased
in infants and the elderly and in skin that has suf-
fered chronic solar injury. Technical factors that
result in false negative results include improper
technique, too short or too long interval fromve control >3 mm wheal and >10 mm flare, due to
n.
comparability and interpretation.
ding.
Devices for which a 3-mm wheal would be significant Devices for which a wheal >3 mm should be
used as significant
Device 99th Percentile of reactionsat the negative control sites Device
99th Percentile of reactions
at the negative control sites
Quintest (HS) puncture 0 mm DuoTip (Lincoln)
twist
3.5 mm
Smallpox needle (HS)
prick
0 mm Bifurcated
needle(ALO)
prick
4.0 mm
DuoTip (Lincoln) prick 1.5 mm MultiTest
(Lincoln)
Puncture -
4.0 mm
Lancet (HS) puncture 2.0 mm Bifurcated
needle (ALO)
puncture
4.5 mm
Lancet (ALK) Puncture 3.0 mm Quick Test
(Pantrex)-
4.0 mm
DermaPICK II
(Biomedixs) Prick or
puncture
0 mm Greer
Track(Greer)
3.5 mm
Table 7.Wheal size indicating a positive response to skin tests using various devicesa. Abbreviations: HS, Hollister Steir; Greer, Greer Laboratories;
ALO, Allergy Labs of Ohio; Lincoln, Lincoln Diagnostics; ALK, ALK America. Positive response is defined as a wheal greater than 99% of wheals generated by the
administration of saline to the subject's back by the same operator. a. Adapted from Bernstein IL, Li JT, Bernstein DI et al. Allergy diagnostic testing: an updated
practice parameter. Ann Allergy Asthma Immunol 2008; 100(Suppl 3):S1–S148.12
Volume 13, No. 2, February 2020 11application to measurement and extracts of
reduced potency due either to aging of the extract
or poor original quality of the extract.
Since the interpretation of skin tests can have
significant impact on daily life, in terms of avoid-
ance measures and therapies, the specialist must
pay attention to different clinical aspects:
 positive tests may occur in absence of clinical
relevant symptoms (sensitization);
 negative skin prick test results can miss the pres-
ence of IgE-mediated sensitization (e.g., due to
lack of major allergens in commercial extracts);
 negative SPT results in children do not exclude
the possibility of development of allergic dis-
eases in the future.
When the SPT result is not clear or does not
correlate with clinical history, a serum specific IgE
assay or, more rarely a challenge with the culprit
allergen, may be needed (Table 9).Since the interpretation of SPT results is crucial
for a proper treatment approach, in order to find
out “reading keys” for interpretation of test results, a
GA2LEN (Global Allergy and Asthma European
Network) survey investigated the correlation be-
tween SPT wheal size and self-reported clinical
relevance (i.e., symptoms related to asthma, allergic
rhinitis, atopic dermatitis, and food allergy) for 18
allergens tested in 3068 patients in 17 European
centers. With the exception of Aspergillus fumiga-
tus, with larger wheal sizes the prevalence of allergic
symptoms increased significantly. This correlation
was variable among the different allergens, ranging
from 40% (Blatella) to 87–89% (grass, Dermatopha-
goides pteronyssinus) of the positive SPT wheals
associated with patient-reported clinical symptoms.
In general, children with positive SPT were less
symptomatic than adults in relation to hazel tree
(P < 0.001) and dog (P < 0.001); no difference was
found for house dust mites. The frequency of
symptoms was slightly higher among skin test pos-
itive women than skin test positive men for hazel
tree (P ¼ 0.012), dog (P ¼ 0.031), and Dermato-
phagoides pteronyssinus (P ¼ 0.064). Furthermore,
 Tests are placed too close together (<2 cm), and overlapping reactions cannot be separated visually.
 Induction of bleeding, possibly leading to false positive results and increased risk of systemic reaction.
 Insufficient penetration of skin by puncture instrument, leading to false negative results. This occurs
more frequently with plastic devices.
 Spreading of allergen solutions during the test of when the solution is wiped away.
Table 8. Common errors in skin prick testing. Adapted from Mansmann HC, Jr, Bierman CW, Pearlmann DS (eds). Allergic diseases in infancy, childhood
and adolesence.1980: p.289, with permission. Copyright, Elsevier; Bousquet J et al. Practical guide to skin prick test in allergy to aeroallergens. Allergy 2011.
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frequency of symptoms in the Mediterranean vs.
Nordic and Central European regions was noted in
relation to positive SPTs to hazel tree and dog; on
the contrary, no differences were found for grass or
house dust mites. Regarding the correlation be-
tween positive SPTs and physician-reported diag-
nosis, positive SPT for grass (OR 2.96, 95% CI 2.4–
3.7), cat (OR 2.0, CI 1.6–2.6), Dermatophagoides
pteronyssinus (OR 1.7, CI 1.4–2.1) and hazel tree
(OR 1.7, CI 1.1–2.5) statistically increased the risk of
allergic rhinitis. Positive SPT to Dermatophagoides
pteronyssinus (OR 2.2, 95% CI 1.8–2.6), cat (OR 1.4,
CI 1.1–1.8), and grass (OR 1.2, CI 1.0–1.5) signifi-
cantly increased the risk of developing asthma,
particularly in children (OR 4.2, CI 3.4–5.2). Positive
SPT reaction to cat (OR 1.3, 95% CI 1.0–1.7) and
grass (OR 1.3, CI 1.0–1.6) were slightly correlated
with a major risk for atopic dermatitis, especially in
children (OR 1.5, CI 1.2–1.9) and in females (OR 1.5,
CI 1.2–1.9). Cutaneous positivity to birch (OR 1.7, CI
1.1–2.6) augmented the risk of food allergy, partic-
ularly in females (OR 1.4, CI 1.1–1.8). For each
allergen, the wheal size in mm (ranging from 3 to
10 mm) with an 80% positive predictive value (PPV)
for clinical relevance was calculated and reported in
a GA2LEN “reading key” form that can be a useful
tool for interpreting SPT results.14
Intradermal test
General aspects
In a patient with a strong clinical suspicion of an
IgE-mediated disease with negative skin prick Consider a skin prick test result to be positive if the
control.
 Consider a skin prick test result negative if the wh
simultaneous histamine control.
Table 9. Recommendations in SPT interpretationtests, the intradermal test (IDT) can be considered.
IDTs are frequently used for inhalant allergen
sensitization in the United States. Challenge
studies have not confirmed the predictability of the
test, however, it could be applied in specific situ-
ations (i.e., IDTs to foods are sometimes utilized for
delayed food anaphylaxis from alpha-gal al-
lergy).15 IDTs are applied when assessing
hypersensitivity to drugs or hymenoptera venoms
(see below).
It is important to consider the relative advan-
tages of prick and intradermal testing (see
Table 10).
Intradermal testing (IDT) is important to
reveal both immediate IgE-mediated allergy
and delayed-type hypersensitivity. When used
for type 1 allergy diagnosis, it is characterized
by an increased risk for adverse reactions, thus
requiring high levels of technical and interpreta-
tive expertise: for this reason, it is generally
restricted to a clinical setting where emergency
equipment and treatment are readily avail-
able.16,17 Delayed IDT readings are performed
for delayed reactions, but will not be discussed
in this manuscript.
Indications and contraindications
IDT is usually not required for the diagnosis of
respiratory allergy. It is mainly indicated in case of
suspected respiratory allergies with negative SPT,
venom allergy and drug allergy. It has an estab-
lished place in testing b-lactam (in particular,wheal diameter is 3 mm greater than the negative
eal diameter is less than 3 mm with a positive
Prick test Intradermal test
Simplicity þþþþ þþ
Speed þþþþ þþ
Interpretation of positive and negative reactions þþþþ þþ
Discomfort þ þþþ
False-positive reactions Possible Likely
False-negative reactions Possible Rare
Reproducibility þþþ þþþþ
Sensitivity þþþ þþþþ
Specificity þþþþ þþþ
Indicative of IgE antibodies Yes Yes
Safety þþþþ þþ
Testing of infants Yes Difficult
Table 10. Relative advantages/disadvantages of prick and intradermal allergy skin testing. Adapted from Adkinson: Middleton's Allergy: Principles
and Practice, 7th ed. 2008. Chapter: 71 – In Vivo Methods for the Study of Allergy. Pascal Demoly, Jean Bousquet, and Antonino Romano.229
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be used for testing a number of other drugs such
as insulin, opiates, anesthetics, neuromuscular re-
laxants, proton-pump inhibitors, enzymes, and
chemotherapeutic agents.18–20
Contraindications for IDT include:
 Diffuse dermatological conditions, such as
eczema, urticaria, and dermographism;
 Poor subject cooperation;
 Patients being unable to stop antihistamines/
other interfering drug treatments;
 Food allergy*, for lack of specificity21,22
 *May be utilized in specific situations (i.e., IDT for
foods are sometimes utilized for delayed food
anaphylaxis from alpha-gal)15
Relative contraindications/precautions:
 Persistent/unstable asthma;
 Pregnancy (due to risk of anaphylaxis with hy-
potension and uterine contractions);
 Infants or younger children.Technique
In IDT, allergens (usually, 0.02 mL) are injec-
ted intradermally with small needles to produce
a small bleb, and the outcome measure is an
increase in the size of the wheal with flare re-
action at 20 minutes. Allergenic extract must be
diluted (10–1000 fold or more) from the con-
centrations used for SPT. IDT should always be
preceded by SPT including negative and posi-
tive controls.
The skin end point titration can be defined as
the intradermal injection of allergens at increasing
concentrations to measure their allergic response.
This is typically done for venom and drug allergy
assessments but not for inhalant allergens. To
avoid severe allergic reactions, testing starts with
highly diluted extracts. After 15–20 minutes, the
injection site is measured in terms of the size of the
wheal and flare reaction. The end point, typically, is
the concentration of antigen that causes an in-
crease in the size of the wheal. For other Au-
thors,23 the endpoint is the first dose of antigen
provoking minimal erythema.
This method allows one to grossly quantify the
individual's skin response and, subsequently, their
degree of allergic sensitivity. Titration methods for
1. Skin tests should never be performed unless a physician or other health-care provider professional
capable of treating anaphylaxis is available immediately to treat systemic reactions.
2. Emergency equipment and therapies to treat anaphylaxis, including epinephrine, should be
available in facilities in which allergy skin testing is performed.
3. The clinical status of the patient should be evaluated before testing.
4. Caution should be exercised and allergy skin testing possibly postponed if subjects are having
allergic symptoms.
5. The concentrations and storage of the testing reagents should be appropriate.
6. Negative and positive controls must be performed with each allergy skin test session.
7. Allergy skin tests should be performed on normal skin, preferably the volar surface of the forearm or,
if needed, on the upper back.
8. Patients should be evaluated for dermographism to avoid false positive results.
9. The medications taken by the test subject should be recorded and the time of discontinuing
medications that would suppress a histamine skin response should be documented.
10. Allergy skin test results should be measured at the appropriate time.
Table 11. Type I skin testing summary precautions. Adapted from Adkinson: Middleton’s Allergy: Principles and Practice, 7th ed. 2008. Chapter: 71 –
In Vivo Methods for the Study of Allergy. Pascal Demoly, Jean Bousquet, and Antonino Romano.229
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Precautions and contraindications of all type I skin
testing
Adverse reactions
The prick/puncture test is safe, with systemic
reactions occasionally observed with commercial
extracts. Foods were identified as the most rele-
vant trigger (75%), with nuts having the highest
risk. In general, history of severe allergic symptoms
and large skin test reactions were recognized as
predictors of possible severe adverse reactions to
allergy skin testing (Table 11).
Frequency of skin testing
Skin tests may be repeated for a variety of rea-
sons including: changes in clinical manifestations
or exposures; lack of clinical correlation with
sensitization patterns; or the resolution of venom
immunotherapy. However, routine repeated skin
testing is not recommended.
Age for performing skin testing
Prick/puncture tests may be performed at any
age if indicated, recognizing that positive reactions
tend to be smaller in infants and younger children
(<2 years), and in the elderly.
IN VITRO DIAGNOSIS
General concepts
Identification of the causative allergen (usually an
allergenic protein) responsible for the causation ofallergic disease is the main purpose of the allergy
diagnostic evaluation. The identification of biolog-
ical sources having allergenic properties dates back
more than 100 years, and it is still in progress. Raw
extracts obtained from allergenic sources have
been used for decades to help demonstrate clini-
cally relevant sensitization by means of skin testing,
as well as provocation testing, such as oral or
mucosal (nasal, conjunctival or bronchial) chal-
lenges. Since the purification of IgE in 1967, sero-
logical testing has become a commonly used test in
the evaluation of allergic diseases.25
Using the first in vitro specific-IgE tests, some
drawbacksof in vitro allergy testingwere reported,26
but the progressive introduction of high-
performance laboratory-based IgE methods, partic-
ularly after the development of second-generation
in vitro systems,27 has greatly increased their
diagnostic accuracy. Currently, automated
workstations reduce the required labor, costs and
errors, thus improving the consistency of in vitro
tests. To date, the results achieved with in vitro
specific IgE measurement and skin testing are
nearly comparable with some well-known advan-
tages and disadvantages for each diagnostic
approach.28,29 The main problem with in vitro tests
concerns the intrinsic nature of the crude extracts
used, which are often are an unpredictable mixture
of allergenic and non-allergenic substances. In
addition, different producers have different extracts
and the same producer may have different extract
from material collected in different years.30 Despite
these intrinsic differences which were an obstacle
Classification of
allergen extract
Classification of
molecular
components
Cross reactivity of
molecular
components
Risk of
molecular
components
Frequency of
molecular
components
Evolution of
molecular
components
Susceptibility
of molecular
components
Inhalants Inhalants (Phl p 1) Genuine (Phl p 1) Potentially
dangerous (Ara
h 1)
Frequent
(major
component)
Phl p 1
Age related
(Bos d 1)
Heat
Sensitive:
Mal d 1
Resistant:
(Pru p 3)
Food Food (Mal d 1) Pan allergen
Phl p 12
Virtually
innocuous
(Ara h 8)
Rare (minor
components)
Phl p 2
Related to
allergy march
(Gal d 1)
Low pH
Sensitive:
Mal d 1
Resistant:
(Pru p 3)
Contact (latex) Contact (latex)
(Hev b 6)
Cross-reactive
Bet v 1
Related to
allergy march
(Phl p 12)
Gut
peptidase
Sensitive:
Mal d 1
Resistant:
(Pru p 3)
Hymenoptera Hymenoptera
(Ves v 5)
Table 12. Different classification of allergens and molecular components are based on specific functional, clinical or biochemical characteristics (exemplary allergens in parentheses)
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15
Allergen extract positive but its molecules negative
(a) Serum IgE binds only to extract's molecules that are not (yet) available in molecular assays.
(b) molecular assay less analytically sensitive than the extract-based assay
Allergen extract negative but its molecules positive
(a) Serum IgE binds to molecules tested as components which are missing or in low abundance in the
extract.
(b) Extract assay less analytically sensitive than the molecular assay
Allergen extract positive but its genuine components are negative
(a) Serum IgE binds only to highly cross-reactive, minor allergenic molecules or CCD determinants
Allergen extract less positive than the added molecular assay level
(a) Serum IgE binds to molecules tested as components being of low abundance in the extract.
Table 13. Interpretation of non-concordance between allergen extract and allergen molecular IgE assay results (modified from Matricardi,
Kleine-Tebbe 2016 144)
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usedasallergensource for in vivoand in vitro tests for
several decades. However, during the first years of
the 1990s, molecular allergists began the
production of recombinant allergens (termed
components) that were thus used as reagents for
in vitro diagnostics. It was immediately evident that
molecular components did not completely
correlate with the results of SPT and of sIgE tests for
a number of reasons that will be discussed. But, it
was also evident that the specific characteristics of
each molecular component, when used in
diagnostics, provided a real added value. Indeed,
we are now able to classify components according
to different strategies, represented by well-defined
molecular characteristics (Table 12).
The full assessment of molecular components is
quite complicated: at the moment (September
2018), in fact, >4700 distinct molecules have been
described, including>3200 isoforms (such as Ara h
2.0101, Ara h 2.0102, Ara h 2.0201 andAra h 2.0202
or Ara h 2) (http://www.allergome.org/script/
statistic.php). This very large number of potential
reagents offers unexpected possibilities in allergy
diagnostics. So, in this chapter, the characteristics of
in vitro IgE tests will be discussed in light of themost
recent advances in basic and clinical research.DIAGNOSTIC STRATEGY
Before describing the different methods avail-
able and their extended technical possibilities, it is
necessary to analyze the medical and diagnostic
contexts in which these in vitro methods are used.
The comparison of the results obtained by usingSPT in vivo and sIgE in vitro started virtually
immediately after the development of laboratory
methods for the detection of specific IgE. Two
groups of spirited partisans arose. SPT followers
maintained that SPT is in general simple and
painless; but sIgE supporters considered that SPT,
in small children, can be really difficult, requiring a
certain amount of co-operation from the patient.
SPT followers maintain that in vivo assessment of-
fers quick results (tens of minutes) but sIgE fol-
lowers showed that modern sIgE requires just a
couple of hours. SPT followers indicated that SPT
can be performed with virtually any allergen (the
prick-to-prick procedure) but sIgE countered by
maintaining that the number of allergens to be
tested in vitro is just limited by the costs. Moreover,
sIgE followers noted that sIgE assays can be per-
formed by any laboratory technician, are not
affected by anti-histamine drugs, the results –
despite certain differences between reagents and
producers – are not dependent on the operator's
experience, and potentially dangerous allergens
are not administered to the patient. Nowadays, the
two parties (SPT followers and sIgE followers) are
still debating.33–35 As a general concept, SPTs are
more sensitive than in vitro tests, whereas serum
specific IgE detection is more quantitative than
SPT. This discussion could have certain
significance only if in vitro assays should replace
SPT in the future (for example, if a reagent for
SPT cannot be produced like for a drug). But at
present, SPT are still available and the top-down
strategy of allergy diagnosis36 remains the most
frequent approach followed in clinical allergy
diagnostics. However, in this context, it should be
noted that SPT is considered a functional test by
Volume 13, No. 2, February 2020 17which the skin reactivity to an allergen (no matter
whether mediated by IgE or not) is measured by
the diameter of the wheal. On the contrary,
different sIgE tests are assays used to detect the
presence of IgE antibodies able to bind an
extract allergen or a molecular component. So,
specific IgEs are suitable to identify the presence
of serum IgE to one or more allergens provided
that IgE are present and detectable (Table 13).
Sensitivity and specificity can be evaluated, for
every new laboratory assay, by comparing the
results of the novel test to that of a gold
standard. For specific IgE, a gold standard does
not seem to exist. Indeed, it is a common notion
that every subject recognizes antigens or
allergens on the basis of her/his genetic
substrate: so, certain epitopes are recognized by
certain haplotypes, while others are not. In
addition, in vitro assays are in general based on
an excess of allergen bound to the solid phase:
for this reason, a large low-affinity immune
response cannot be easily distinguished from a
high affinity one.
To this it should be added that, like any other
serological method, every specific IgE test has
certain characteristics, related to the structure of
the solid phase (if any), the amount of allergen in
the tube, the time and conditions for the incuba-
tion, the characteristics of the anti-IgE, the
behavior of the labeled antigen the detection
method used (like Enzyme Immune Assay [EIA] or
Chemiluminescence [CL]), and the dynamic range
of the reading etc. For example, in vitro assays
based on chemiluminescence are more positive (in
particular in the presence of low levels of specific
IgE) than assays based on ELISA or similar tech-
niques. So, in the presence of a positive result with
CL and a negative result with ELISA, the question
that must be asked is: is this a false positive result
or is this result the demonstration of the presence
of a small (but specific) IgE response to the
allergen? In other words, is ELISA underestimating
the presence of sIgE? Along this line, even the
solid phase structure may have an unexpected
effect on the serological result. For example, it has
been shown that certain solid phases express
CCD, thus causing false positive results in patients
with sIgE to CCD.37 What is known from basic
immunology is that a positive result can be
observed in any situation just by changing theexperimental conditions or increasing the
sensitivity of the assay itself. Antibodies are
characterized by a spectrum of specificities for
the antigens: they are extremely specific under
certain experimental conditions but, in other
conditions, antibodies can efficiently recognize
similar epitopes. So, the answer to this question
lies squarely in the hands of the allergist who
must decide whether what is observed is just a
sensitization or a real allergy. Keeping in mind all
these relevant points, it is evident that the
comparison between methods may be
sometimes an oversimplification of the problem,
causing more confusion rather than shedding
light on the argument. Along this line, from a
practical point of view, an allergist should build
her/his experience on a well-defined in vitro test,
in order to have a clear strategy for the interpre-
tation of the in vitro results. All these consider-
ations are even more relevant when the tools of
molecular allergy diagnostics are used. Indeed, at
present, if an accurate diagnosis of allergic sensi-
tization is required, specific IgE to allergen extracts
are not always as precise as wished for, and a more
specific description of the IgE profile may be
mandated. This is particularly true when allergen
immunotherapy (AIT) is provided to the patient.
Even though large discussions on this topic are still
ongoing, suggestive data seems to indicate that
AIT is probably more effective in patients sensi-
tized to genuine allergens,38–43,42,43 while its
activity is less impressive in patients with a
sensitization to cross-reacting components or
pan-allergens. In this context, the in vitro evidence
of specific IgE involvement in the patient's symp-
toms associated with the detection of IgE specific
for genuine components seems to be the entry
level diagnostic for patients that could have a real
modification of their allergy by AIT.
These considerations should be always be taken
into account. One cannot directly compare the two
methods (SPT and sIgE tests) as they are pro-
foundly different in many aspects. Specific IgE (to
the allergen extract or to molecular components)
provide a real added value in those cases where
the allergist requires a precise diagnosis before
starting AIT and to identify accurate therapeutic or
prophylactic strategies in food and hymenoptera
allergy. Along this line, it should be clearly noted
that specific IgE tests are poor or not significant at
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Although a few drug reagents are available (in
particular, antigens derived from penicillin and
some peptide hormones) they do not encompass
the requirements of allergists in this field.Total serum IgE
In 1967, the first solid-phase sandwich immuno-
assay for the measurement of total and specific IgE
was described.44 The amount of total IgE was
considered in the early studies as the simplest way
to identify allergic subjects,45,46 but it became
evident soon that total IgE levels could not be
considered a reliable marker of allergy status.47,48
IgE levels significantly higher than the normal
threshold, are usually associated with atopic
disorders, but also with other conditions (see
below). On the contrary, low or normal values do
not exclude the presence of IgE-mediated dis-
eases. As a consequence, total levels of IgE should
be carefully interpreted and not considered as an
indication for the presence of allergic diseases.
Serum IgE concentration is largely age-
dependent. Very low levels of IgE are found in
cord serum (<4.8 ng/mL) with a progressive in-
crease observed up to the age of 15 years, similar
to serum IgA. Total serum IgE then declines from
the 2nd through the 8th decades of life.
Very high IgE levels are observed in parasitic
infestations, rarely in multiple myeloma patients
producing IgE, and in some primary immunodefi-
ciencies (e.g., Immune dysregulation poly-
endocrinopathy enteropathy X-linked syndrome
(IPEX), Omenn syndrome, Wiskott-Aldrich syn-
drome, Comel-Netherton syndrome, hyper-IgE
syndrome and atypical complete Di George syn-
drome).49 Allergic broncho-pulmonary aspergil-
losis (ABPA) is the only clinical condition described
to date, where the presence of high levels of IgE is
strictly related to disease severity.50 IncreasedNormal Total IgE level
Absent sIgE Non-allergic patient
Present sIgE Patients with sensitization(s)
Table 14. Relationships between Total IgE and specific IgE results. a. Th
tested in the in vitro assay, or the specific allergen is missing in the allergen panserum IgE levels can be seen also in a proportion
of smokers.
In the past, total IgE levels were calculated using
a number of immunoassays that utilize specific
antibodies for human IgE as both capture and/or
detection reagents. These antibodies, in the vast
majority of cases, are conjugated on a solid phase
(capture antibody) and/or directly labeled with
radio-nuclide, enzyme, or fluorophore. Automated
platforms significantly improved accuracy and
reproducibility, increasing both specificity and
sensitivity as well. Commercially available assays
have been cross-standardized to a common pri-
mary human IgE standard (WHO 11/234).51 Total
IgE values are currently reported in International
Units of IgE per volume (IU/mL); a conversion
factor (1 IU ¼ 2.42 ng) is sometimes applied.
Nowadays it is very common to be reported in its
equivalence of kU/L.
Different scenarios can be considered. Table 14
shows these different conditions.
Allergen-specific IgE assays
General concepts
The laboratory methods
The measurement of specific IgE recognizing
allergenic epitopes can be achieved both through
the usage of single reagents (singleplex) or with a
pre-defined panel of a number of molecules to be
tested simultaneously (multiplex).52
In general, there are some positive and negative
aspects for both in vitro allergy testing methods
that distinguish between the two different
techniques.
The structure of the assay
Since the time of the original assays,25 the
assay for the detection of specific IgE has been
based on the classic sandwich technique withHigh total IgE level
See non-allergic high IgE conditionsa
Patients with sensitization(s)
is condition may also occur when specific IgE to the relevant allergen are not
el used.
Producer Solid phase Allergens Patient'sserum Anti-IgE
Anti-IgE
Labelling
Enzyme
substrate
Stop
solution
Reading
system
RAST Sephadex or
paper
Extract 0.05 mL/
sample
Polyclonal 125 I none NN Gamma-counter
Phadia Polymer of
hydrophilic,
highly
branched
cellulose
derivative
enclosed in a
capsule.
Extract or
recombinant
bound
covalently to
the solid
phase
0.04 mL Mouse
monoclonal
anti-human
IgE
ß-
Galattosidase
4-metilumbelliferil-
ß-D-galattoside
Na
Carbonate
Photometer
Siemens Streptavidin-
covered
polystyrene
ball
conjugated
with
streptavidin-
Extract or
recombinant
allergens
covalently to
soluble
biotinylated
polylysine
polymers.
anti-IgE
antibody
(mAb ?
pAb?)
Alkaline
phosphatase
4-methoxy-4-(3-
phosphatephenyl)-
spiro-(1,2-
dioxetane-3,20-
adamantane)
N.S. Light emission
detector
(chemiluminescence)
Hycor Magnetic,
streptavidin-
coated
microparticles
incubated
with a
biotinylated
allergen
Extract or
recombinant
0.04 mL A mixture
of two
mouse
monoclonal
Anti-IgE
Horseradish
Peroxidase
acridin based
chemiluminescent
substrate
N.S. Light emission
detector
(chemiluminescence)
Euroimmun Paper Extract or
recombinant
1000 mL Alkaline
phospatase
Water Scanner
Table 15. The most commonly used systems for specific IgE detection include the following distinct components
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Producer Total number ofavailable allergens
Number of
extract allergens
Number of
molecular
component
Laboratory method
Thermofisher 566 460 106 (of which 28 N
and 78 R)
Enzyme
immunoassay
Siemens 439 413 26 (of which 20 N
and 6R)
Chemiluminescence
Hycor 79 69 10 Chemiluminescence
Euroimmun (in
92 strips)
316 285 31 of which 20 R and
11 N)
Dot blot
Table 16. Allergen extracts and molecular components available from different commercial sources in single-plex allergy diagnostics
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represented by the solid phase, the allergen
conjugated with the solid phase, the patient's
serum, the anti-IgE antibody, the labelling of the
anti-IgE, and the substrate (if any) for the pro-
duction of the signal. Washing and stop reagents
are also present. However, the specific charac-
teristics of the former are fundamental for the
results while the latter (washings and stop solu-
tion) are less relevant.
The main reagents used in the assay
 The reaction site (carrying the allergen) can be: a
polyethylene cap with an internal sponge matrix,
a plastic (polyethylene) or glass tube, a plastic
microtiter plate well, a plastic stick, or a carbo-
hydrate filament-coated silicone chip. To
ameliorate the antibody-binding capacity, a va-
riety of carbohydrate-based allergo-sorbents
(other than Sephadex and paper), such as
agarose and microcrystalline cellulose, can be
used. The most important advance was the
development of an encapsulated hydrophilic
carrier polymer to which the allergen is cova-
lently coupled.53
 The allergen-containing reagent can be repre-
sented by a solid-phase allergo-sorbent or
liquid-phase conjugated allergen. This is the
most complex and highly variable component in
terms of preparation from raw material, quality
control and validation,54 conferring specificity
on the IgE antibody assay. For example, RAST
represented a non-competitive, immuno-radio-
metric assay that used allergen coupled on
allergo-sorbent paper discs. Subsequently
several other variants of the same assay weredeveloped.55,56 In other systems, a liquid-phase
is used with coupled anti-IgE that captures free
serum IgE. These systems seemed not to
recognize low affinity IgE, claimed to have less
relevance from a clinical point of view, and have
been rarely used.They are described as research
tools.27 Usually, each allergen represents a
distinct reagent, but a multi-allergen assay can
be achieved by mixing a group of allergens into
one reagent. In addition, solid-phase reagents
are sometimes supplemented with recombinant
molecules in order to improve the extract's
performance (e.g., latex extract supplemented
with rHev b 5).57
 The nature of allergens used in the in vitro test
for specific IgE.
As previously mentioned, allergens can be both
raw extract allergens or single molecules. These
molecules can be obtained by recombinant DNA
technology or by biochemical purification from
natural extracts (Table 16). Of note, raw extracts
and highly purified extracts have certain post-
translational modifications (such as glycosylation)
that are absent in molecules produced in E.coli.
There are two distinct types of molecules used in
assays for specific IgE. The first one is represented
by the so-called “genuine” markers of exposure,
such as Phl p 1 from timothy grass pollen or Par j 2
from pellitory. These allergenic molecules belong
to a specific biological source and are able to not
only identify IgE sensitization, but also point to-
wards the presence of the related allergenic
sources in the environment.58,59 On that basis,
epidemiological studies became possible. The
first large scale surveys based on the routine use
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understanding of allergic sensitization in different
geographical regions, and provided prevalence
data for the development of molecule-based
immunotherapy.62 The second group of
molecules is represented by the so-called “cross-
reactive molecules” or “pan-allergens”.63 They are
families of strictly related proteins that are widely
distributed among different species because they
are involved in crucial cellular processes. Several
panels of pan-allergens families are now identi-
fied (e.g. Bet v 1–like molecules, lipid transfer
proteins, profilins, tropomyosins, parvalbumins,
lipocalins, serum albumins, 2S albumins, vicilins,
and 11S albumins). These panels of homologous
molecules facilitate the diagnosis of sensitization in
individual patients and also enhance the accuracy
of epidemiologic research. Furthermore, despite
the high sequence identity among components of
every single group of pan-allergens, IgE co-
recognition of homologous molecules64 does not
always reflect what is predicted on the basis of
amino acid sequence, but rather on the
molecular 3D-structure.65 The use of several
representative homologous molecules within
every single pan-allergen group would provide
more information on IgE epitope recognition,
allergen structures, and, possibly, the identification
of clinical phenotypes.66 The clinical picture, in
fact, depends on which exposures determine the
type of sensitization pattern (as previously
mentioned) and may range from total absence of
symptoms, (despite the presence of IgE reactivity)
to severe, life threatening generalized
reactions.67–69
 The human sample. Both human sera and
plasma have been used in diagnostics. In the
original assays, undiluted serum samples were
used. Following the introduction of novel and
automated assays, the sample volume was
reduced. It is evident that the concentration of
the human sample in the test tube determines
the results. Every laboratory method has its
specific serum volume and concentration cali-
brated on the other reagents, such as the
allergen amount and the anti-IgE “detection”
antiserum (or monoclonal antibody)
 The anti-human IgE Fc detection reagents (ε
heavy-chain specific) usually are polyclonal rab-
bit, goat, sheep, horse, or murine anti-IgEmonoclonal antibodies. Combinations of poly-
clonal and monoclonal (mAb) anti-human IgE
and labeled human a-FcεR170 have also been
used to detect human (but also horse, dog,
and cat) IgE.
 Antibody labelling and detection methods. Anti-
human anti-sera or mAb were originally labeled
with 125I (the original Radio Allergo-Sorbent Test
– RAST). Nowadays, other labelling techniques
using enzymes such as b-Galactosidase (b-Gal),
Alkaline phosphatase (AP), and Horseradish
Peroxidase (HPO) are used. A strictly related
reagent is represented by the enzyme sub-
strates: from pNPP for AP to “perox” for HPO.
The sensitivity of the assay is improved when
specific substrates (named chemiluminescent)
are used. In this second case, a different reading
method is necessary: indeed, for substrates
emitting in the optical range, a photometer is
needed, while for chemiluminescence, a fluo-
rometer is required.
 The calibration system (e.g., reference serum
containing a known amount of IgE) defines the
level of IgE antibody measured by the assay
creating a calibration curve. The reference curve,
as stated above, can be obtained by means of a
“heterologous” or “homologous” interpolation
approach. In the first approach, quantitative
allergen-specific IgE antibodies are expressed in
IUA/mL, where the “A” means “allergen-specific”,
differentiating this measurement from the IU/mL
utilized for the total IgE assay. In the second, the
measurement is indicated by arbitrary units us-
ing a homologous calibration curve.27
 The reaction buffer medium (salts, proteins)
normalizes pH and gives a protein matrix for the
analyses of interest to warrant the nonspecific
binding.
 The control samples, containing positive serum
controls and not containing (negative serum
controls) allergen-specific IgE antibody.
 The data-processing software, for managing of
results and data processing.Singleplex assay
The presence of allergen-specific IgE antibody
in serum identifies sensitized individuals, and a
large fraction of them can be considered allergic if
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the allergen(s) detected.
A number of articles have been published to try
to define the sensitivity and the specificity of
in vitro IgE tests. This may prove useful for more
epidemiological reasons, if, in the future, in vivo
SPT are abandoned. From a scientific point of
view, it is a common notion that not all allergic
reactions are mediated by IgE. Thus, defining the
sensitivity of an in vitro assay that is well known to
be able to detect only allergen specific IgE, by
comparing it with clinical diagnosis of allergy,
could lead to partially wrong conclusions. The
diagnosis of allergy is a clinical diagnosis. The
presence of specific IgE that could better correlate
with the clinical picture, could be useful to better
define the allergic profile of the patient before
starting AIT. This is particularly true for inhalant
allergy, while for food allergy, the picture is much
more complex. For example, the dynamic range of
specific IgE to inhalant allergens is wide, while the
same range for food IgE is significantly smaller.
Thus, the use of a single interval of reference
values in these two different situations should not
be accepted in a laboratory medicine setting.
Indeed, not all hormones have the same range
interval of reference values either. Although dis-
crepancies remain, the original reference intervals
used for allergens never changed. In the future, a
more accurate approach will be required to define
reference intervals, particularly in the presence of
low concentrations of IgE. In this context, if should
be noted that a certain variability between
different methods (and laboratories) is expected,
as was recently observed.71,72
There are a large number of singleplexed di-
agnostics systems in the world, and four major
ones can be identified (Table 15). Each has specific
characteristics and performances. Probably, this is
not the right place to discuss differences between
different laboratory solutions. Each has pros and
cons. But in general, an IgE profile derived from
one of these four producers is acceptable. As
stated before, the specific characteristics of each
method should be well known to the allergist. So,
at least in follow up (in particular in the pediatric
age), the use of different methods could
sometimes generate results that could be difficult
to interpret and/or manage.From a practical point of view, allergists use the
singleplexed diagnostics in two different manners.
The first is related to the results of SPT performed
in the patient, in order to verify whether a positive
or a negative result is confirmed by the presence
of IgE to that allergen. Using this approach, the
allergist focuses her/his attention to a very select
(and small) number of allergens. In recent years,
the availability of molecular components (identi-
fying both genuine and cross-reacting molecules)
has substantially improved the singleplexed strat-
egy by allowing mixing whole allergen extracts
and selected components, in order to have a clear
description of the IgE profile of the patient.
Nevertheless, it is evident that the allergist, by a
singleplexed and censored choice of the allergen
to be tested, can only detect IgE for the allergens
required. Along this line, in some complex situa-
tions, for example a polysensitized patient with a
large number of positive results by SPT, the list of
allergens and components to be tested could be
long.
Another approach (more focused on primary
care) is related to the use of allergen panels. It is
evident that panels for adults are different from
panels for children, panels for a respiratory allergy
are different from panels for a food allergy, and
panels for northern countries are different from
panels of southern countries, etc. So, the best
approach, should be that every allergist develops
her/his list of different panels suitable for her/his
patients. This could be more difficult in primary
care: for this reason, panels were developed in the
late 1970s but at present their use is limited. A
producer developed many different panels for
different ages, climates, and symptoms. However,
the choice of each allergist still remains funda-
mental. Panels with a mixture of whole extract al-
lergens and molecular components could be a
very interesting method, provided that the signifi-
cance of a positive component is known in primary
care.
The sensitivity of specific serum IgE antibody
measurements could be considered as compara-
ble to that obtained with skin prick testing for
respiratory and food allergy, but only comple-
mentary to the intra-dermal skin test for drug and
venom allergy diagnosis. The accuracy and repro-
ducibility of the modern fully automated systems,
providing reliable quantitative measures, has
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relationship between allergen-specific IgE anti-
body levels in serum and the clinical risk of an
adverse reaction (probability-based risk assess-
ment), especially in the field of food allergy.73–79
Higher risk of adverse reactions to food, as
assessed by the reference standard for the
diagnosis of food allergy, the double-blind
placebo-controlled food challenge, was
associated with defined diagnostic cut-off levels
of food-specific IgE antibody.74 Unfortunately
conflicting results were obtained in similar
studies performed by other investigators
attempting to replicate these findings,75
probably because predictive values should be
carefully defined for each specific population
separately.76
In the last several years, with the continued
development of molecular diagnostics, it has
become possible to perform singleplex assays with
the use of recombinant or purified allergens (i.e.,
not only with allergenic extracts), thus increasing
sensitivity, specificity, and diagnostic accuracy of
the tests.8 The choice of using diagnostic
recombinants in singleplex instead of in
multiplex, is made on a case-by-case basis
(considering previous history and clinical profile)
and in an allergen-dependent manner (i.e.,
allergen source and availability of single
recombinants).
The use of whole allergens and molecular
components has pros and cons as it does in SPT. It
is evident that the sensitivity of molecular compo-
nents, when compared with that of whole aller-
gens, is lower. This is due to many reasons. First,
only in rare situations, a single component is so
frequently positive in sensitized patients that the
molecular component is representative of the
sensitization. For example, Par j 2 is a major
allergen of Parietaria judaica, and in clinical prac-
tice, the correlation between these two reagents is
complete. But, for example, Phl p 1, one of the
major components of Phleum pratense is positive
in 70–80% of patients characterized by a positive
reaction to the extract. To reach 90%, Phl p 1
should be associated with the other major
component, Phl p 5. Second, not every molecular
allergen is available in diagnostics. For this reason,
at present, it is virtually impossible to describe a
positive IgE reaction only by molecular allergen.For example, the IgE profile of dust mites, such as
Dermatophagoides pteronyssinus, can be well
detected by Der p 1, Der p 2 and Der p 10. But
only with Der p 23, a fraction of originally extract-
positive/component-negative sera becoming
available, could the discrepancies between ex-
tracts and molecules be reduced.
As stated before, the singleplexed strategy of
allergy diagnostics is strictly related to the classic
“top-down” approach: the patient is seen by the
allergist, SPT are performed, then if necessary,
specific IgE for a selected panel of allergens are
tested and, in a minority of situations, the study is
deepened by using allergen components, in order
to have a very accurate picture of the IgE profile.
More recently, a totally different approach, the
so called “bottom-up” approach, was introduced
in allergy diagnostics. Patients are originally
screened by the use of a very large panel of re-
agents and, based on those results, the allergist
then decides how many and which other compo-
nents to test to improve the diagnosis and suggest
a treatment. This approach was considered icon-
oclastic by classic allergists, but it may have certain
advantages, at least in a precision medicine
setting, where the best description of the patient's
situation is required for any further decision.
In certain situations the use of recombinants is
more useful and convenient, as compared with
whole allergen extracts, such as in cases of multi-
ple IgE sensitivities, particularly when assessing the
following:
- potential clinical risk and severity of allergic
manifestations;
- presence of cross-reactivities;
- primary IgE sensitization;
- polysensitization that is difficult to interpret.
A representative example is insuring that a
complete screening includes specific IgE for Bet v
1, Bet v 2, and Bet v 4 recombinants to assess the
type of sensitivity to birch (primary sensitization,
possibility of cross-reactivities, and risk assessment
for potential allergic reactions to cross-reactive
foods). Another is the detection of sIgE for Der p
10 which is associated with IgE sensitivity to the
tropomyosin protein family, increasingly the
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and mollusks due to dust mite sensitivity, even if
tropomyosin sensitization is primarily driven by
seafood and not mite.80
Qualitative, semi-quantitative, and/or quantita-
tive IgE antibody immuno-assays are currently
available.
A qualitative assay generates only negative or
positive results. It does not provide any measure-
ment of IgE concentration, but it is defined by the
presence of the analyte above a given positive
threshold level of the assay. If levels are close to
the cut-off point of the system, they can be
considered as “borderline”.
A semi-quantitative assay produces a series of
increasing classes (e.g., from I to VI), thus defining
the amount of the response. These assays are not
characterized by linearity, dilution recovery, or
parallelism of quantitative assays.
A quantitative assay provides the measurement
of IgE antibody concentration, on the basis of the
interpolation from a multipoint calibration
curve,77,78 obtained using both heterologous and/
or homologous methods. A reliable quantitative
assay should report results in units traceable to
an internationally recognized standard (e.g.,
WHO 11/234).51 Unfortunately, it is not possible
to use individual homologous calibrated IgE
antibodies, for each of the hundreds of biologic
sources tested. Therefore, the calibration method
generally adopted is a heterologous interpolation
of specific IgE antibody from a single total serum
IgE reference curve. Quantitative systems results
are reported in gravimetric (mg/L [total serum IgE
assays]) or international units (kU/L [total serum
IgE assays] or kUA/L [allergen-specific IgE anti-
body assays]).
Most specific IgE blood tests are immunoassays
that include enzyme-linked immunosorbent assays
(ELISAs), fluorescent enzyme immunoassays
(FEIAs), chemiluminescent assays, or radioallergo-
sorbent assays (RASTs). Since 2010, the National
Institute of Allergy and Infectious Diseases (NIAID) /
National Institutes of Health (NIH) have recom-
mended discontinuation of the RAST as a diag-
nostic tool for allergy in favor of more sensitive
fluorescence enzyme-labeled assays, in which a
fluorescent antibody binds to the patient's sIgE,and the amount of IgE present is calculated from
the amount of fluorescence. With over 4000 sci-
entific articles showing its clinical value, Immuno-
CAP at the moment is perceived as “reference
standard” for in vitro IgE testing.81 However, the
presence of this antibody only proves
sensitization, not allergy, the latter being
sensitization in the context of clinical symptoms
upon exposure to the allergen.
The “CAP inhibition” technique is a variation of
the direct CAP: allergic serum (containing sIgE) is
first mixed with the soluble unknown allergen; then
a standard amount of the solid-phase (immobi-
lized) allergen is added. The CAP inhibition is
important to evaluate the total allergenic activity of
a diagnostic or therapeutic extract. Furthermore, it
is still performed to distinguish multiple sensitiza-
tions from cross-reactive sensitivities, in particular
as a diagnostic tool in Hymenoptera venom al-
lergy; however, the development of molecular-
based diagnostics in allergy has significantly
reduced the need of CAP inhibition performance
for certain Authors,82 while, for others, the CAP
inhibition still remains fundamental.83–85
ELISA assays can represent a valid alternative to
FEIAs, being relatively simple and inexpensive for
the assessment of serum total and specific IgE for
various common allergens. Their usefulness is
more greatly appreciated where ImmunoCAP is
not available. Academic medical centers may be
able to provide in vitro allergy assays in areas
without ImmunoCAP.86 Various systems currently
employed in assessing allergen specific IgE often
have substantial allergen by allergen discordance
especially in the lower end of the allergen
specific IgE assay range. This is likely due to
variance in the allergens employed in these
systems.
Multiplex assay
Genomic microarrays were developed and
introduced about fifteen years ago in biomedicine
to monitor the expression of many genes in par-
allel and to investigate differences in the level of
mRNA expression from thousands of genes at the
same time, in order to gain information about
transcriptional changes involved in specific path-
ways.87 Genomic microarrays have provided
insight into transcriptional gene expression of
specific biologic pathways in the normal state
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possible application of a proteomic microarray
approach in the diagnosis of allergic sensitization
appeared in the literature in 2002,89 followed by
several other reports90–92 verifying the same
array, widely known as the ISAC (Immuno Solid-
phase Allergen Chip) system. A number of other
studies have been published on the development
of microarray prototypes,.93–106
Currently, IgE detection by means of microarray
systems is classified as an in vitro diagnostic (IVD)
tool.27 A few years ago the first version of the ISAC
microarray became commercially available. It had
74 different allergenic proteins spotted on the
microarray (ISAC74). The number of allergens
immobilized on this microarray is growing and a
version with 112 allergens (ISAC112) is currently
available. The small amount of material necessary
for the process of identification (from 0.1 to
1 ng)107 allows the use of both recombinant and
highly purified natural molecules.
A study compared ImmunoCAP sIgE singleplex
tests and the ISAC 112 IgE multiplex assay in 101
patients sensitized to grass pollens. The ISAC
multiplex test correlated well with ImmunoCAP
singleplex results, with a positive percent agree-
ment (PPA) and negative percent agreement (NPA)
of corresponding allergens varying between 60
and 100% for PPA and 78–97% for NPA.108
Interestingly, a deeper analysis of the ISAC 112's
characteristics also demonstrated that it is a highly
reproducible and accurate method which may be
considered as a single analyte assay in the view of
the EN ISO 15,189 accreditation procedure.109
This was further demonstrated in another
work.110 Other authors108 observed that results
obtained by allergen microarray correlated well
with ImmunoCAP singleplexed results. In
addition, technical improvement seems to
ameliorate some of the less reproducible
properties of the allergen microarray. Monroe
et al.111 showed that their use of a calibrated
fluorescence enhancement (CaFE) technique
seems to more accurately measure probe density
and bound target for a variety of antibody-
antigen pairs.
At the same time, some at least partially unex-
pected cross-reactions between components of
ISAC were identified.112 Not only can nPhl p4, ahighly glycosylated protein cross-react with IgE
specific for CCD, but also nCry j 1, nCup a 1, nCyn
d 1, nPla a 1, and nJug r 2 can be non-specifically
positive in patients sensitized to CCD. For this
reason, the real clinical significance of a positive
nJug r 2 must be carefully evaluated in the context
of other component results and the patient's clin-
ical picture.
Allergen microarrays were also used to evaluate
the presence of specific IgE in fluids different from
serum or plasma. Valenta and co-workers analyzed
the presence of IgE in samples of breast milk.113
Leonardi et al.114 recently showed that in vernal
keratoconjunctivitis (VKC), ISAC is able to detect
the presence of specific IgE to grass, trees, mites,
and animals but also food allergen-specific IgE in
tears. What was particularly interesting was that in
some patients, specific IgE were absent in serum
but detectable in tears. The presence of specific
IgE only in tears of VKC patients reinforces the
concept of possible local sensitization. These two
examples of the use of microarray technology for
specimens different from plasma or serum opens
new fields not only for research but also in clinics.
Another interesting and innovative use of
allergen microarray is the monitoring of Allergen
Immunotherapy. Indeed, it has been recently
observed115 that allergen microarrays are useful to
monitor the development of allergen-specific IgG
responses during SIT, both against the allergen
present in the SIT vaccine as well as against cross-
reactive allergens. This application of the tech-
nique may finally offer a general-purpose tool for
monitoring the immunological effects of AIT,
resulting in better control of the treatment and,
even more, a better understanding of therapeuti-
cally positive and negative results. This data was
further supported by the article of Schmid JM
et al.116 that demonstrated that pre-treatment
allergen component-specific IgE appears to
determine the induction of IgG4 during the
updosing phase. Induced IgG4 seems to suppress
IgE levels on ISAC, resulting in a marked decrease
in ISAC-measured specific IgE levels after updos-
ing of SCIT. They conclude that the decrease in
ISAC IgE levels can be used to monitor the
blocking effect of allergen-specific immuno-
therapy-induced non-IgE antibodies.
A number of studies have been performed in
order to define the conditions where allergen
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clinical pictures. For example, D'Amelio et al.117
argued whether the performance of ImmunoCAP
ISAC 112 is sufficient to diagnose peach and
apple allergies. They concluded that although the
sensitivity of the peach components in ISAC is
improvable, it can be sufficient in their region.115
The same authors118 concluded that the
diagnostic performance of ISAC was adequate
for hazelnut and walnut allergy but not for
peanut allergy. Finally, in another different
situation,119 even if the standard ImmunoCAP
has, for apple and peach, a wider number of
available components (in particular Mad d 3, a
lipid transfer protein [LTP]), the evaluation of Pru
p 3 (largely homologous to Mal d 3) may support
the identification of an apple sensitivity even if
“the presence of sIgE against Pru p 3 in LTP
sensitized patients can be due to cross-reactivity
and should therefore not be used to predict clin-
ical symptoms”.
On the contrary, in idiopathic anaphylaxis120,121
the ISAC array contributed to the diagnosis in 20%
of patients and may offer additional information
where a careful allergy history and follow-on
testing have not revealed the cause of the
anaphylaxis.
Microarray technology is progressively
improving, as shown by the MeDALL-chip which
was developed within the MeDALL European
project (Mechanisms of the Development of AL-
Lergy) and is based on 170 relevant allergens. The
MeDALL chip provided new information for some
allergens and seemed to be more sensitive in
detecting allergic sensitization than ImmunoCAP
sIgE or SPT.119,122
In the period when ISAC 103 and ISAC 112 were
used in clinics, other different attempts to modify
the strategy of multiplexed molecular diagnostics
were developed. The main attempt was related to
the works of the MeDALL group that, in strict
cooperation with industry, developed a novel
microarray by adding more than 70 new compo-
nents to the standard panel of ISAC 112.123 These
new components were comprised of: Peanut
allergens, Almond, cashew and pistachio
allergens, Cow's milk allergens, Wheat allergens,
Olive pollen allergens, Mite allergens, Dog
allergens, Insect venom allergens, Staphylococcusaureus toxins, and Maltose binding protein
(MBP). The clinical features of the MeDALL
microarray were further evaluated during the so-
called “allergen march”, from childhood to
adolescence.124,125 The prevalence of allergic
sensitization increased in all three diagnostic
tests from age 10–16 years. It was similar by SPT
and ImmunoCAP but significantly higher with the
MeDALL-chip at 10 years. All three tests were
comparable for identification of allergic sensitiza-
tion among children with current rhinitis or
asthma.125
A different approach has been developed by an
English/Swedish company that designed and
further implemented a microarray where not only
single allergen components but also extractive
whole components were spotted.126 This
combination of extractive allergens and
recombinant components was tested with other
three allergy test methods (SPT, ImmunoCAP,
and ISAC 112) and a total of 3485 pairwise test
results were analyzed and compared. The four
methods showed comparable results with a
positive/negative agreement of 81–88% for any
pair of test methods compared, which is in line
with data in the literature. The most prevalent
allergens (cat, dog, mite, timothy, birch and
peanut) and their individual allergen components
showed agreement between methods with
correlation coefficients between 0.73 and 0.95.
All four methods revealed deviating individual
patient results for a minority of patients. These
results indicate that microarray platforms are
efficient and useful tools to characterize the
specific IgE profile of allergic patients using a
small volume of serum sample. The results
produced by the Microtest system were in
agreement with diagnostic tests in current use.
More recently, a different tool, termed ALEX (as
in ALlergen EXplorer) was developed by Macro-
ArrayDX in Vienna (Austria). The ALEX test is per-
formed using an array of allergens spotted on a
solid phase by way of nano-particles. ALEX con-
tains 282 reagents (157 allergen extracts and 125
recombinant or highly purified molecules). So, in
this chip, second level diagnostics (represented by
extract allergens) and third level diagnostics (rep-
resented by single molecules) are all available.
ALEX has been evaluated and the quality of ALEX
results has been described.127 In consideration of
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components and the significant complexity of the
interpretation of the results (at least for non-
professional molecular allergists), ALEX has been
linked to a new version of the expert system,
Allergenius, originally developed for the interpre-
tation of ISAC results.128 In its present form, ALEX
seems to be a good reagent for the “bottom-up”
strategy of allergy diagnostics.
Another group of tests are represented by the
multiple allergen simultaneous tests (MAST)-
immunoblot, such as EUROLINE, which is a
commercially available assay for component
resolved allergy diagnostics based on the immu-
noblot technique. One “line blot” consists of
several membrane chips containing allergen
components coated in single lines. The membrane
chips principle allows for optimized coating con-
ditions of the respective components. Due to the
simultaneous determination of sIgE to different
allergen components, a sensitization profile can be
generated in a single test run using low amounts of
serum. This technique allows the detection of
specific IgE quickly and efficiently with the use of
immunoblot strips containing optimized combi-
nations of relevant allergen components. Each
profile is tailored to a specific indication: several
indication-specific profiles for molecular allergy
diagnostics are already available for inhalant al-
lergens, insect venoms, and food allergens. When
compared to ImmunoCAP, substantial agreement
between MAST and ImmunoCAP was found for
inhalant, food, and venom allergens thus repre-
senting a valid diagnostic alternative.129
A flow cytometric bead array (CBA) has been
developed to detect soluble factors.130,131 Naked
fluorescent micro-beads (Flex Set), can also be
customized to detect specific antibodies,132,133
but not many reports on this specific application
are found in the literature.134 CBA Flex Set,
unlike other micro-bead-based systems,135 is
designed for flow cytometry, an instrument
widely used in almost all routine or research
laboratories. The feasibility of the CBA Flex Set
for specific IgE detection in human sera using
allergenic molecules coupled on the fluorescent
micro-beads, thus obtaining a “flexible” micro-
array for testing IgE, has been demonstrated.136
The system was named Allergen Bead Array
(ABA), and the simultaneous measurement of upto thirty different micro-beads can be carried out
just using the Fluorescence-Activated Cell Sorting
(FACS) facilities. The opportunity of multiple fluo-
rescence parameters evaluation could also permit
the measurement of distinct antibody isotypes
involved in antigen recognition in the same
sample.136
Some criticisms have arisen against the multi-
plex approach, including poor flexibility in the list
of allergens and the possible lack of relevant al-
lergens. The allergist is forced to test the entire set
of molecules in the commercial product, and it is
not possible to test a “patient-tailored” set of
molecules. Despite this, the allergen array based
approach is in line with the modern concept of
“precision medicine”. However, this approach may
sometimes generate more questions than answers
and complicate the management of, and the rec-
ommendations for, a specific patient.137 A recent
paper compared the classic top-down approach
(represented by the visit of the patient, then SPT,
then — if considered useful — by specific IgE to
whole extract allergens and/or single components
and, finally, in a very select number of cases, the
use of multiplexed IgE detection assays) and the
so-called “bottom-up” strategy, represented by the
immediate analysis of the patient's IgE profile (the
patient's phenotype) followed by in vitro and
in vivo tests useful to better describe the patient's
endotype and how they can relate to therapeutic
management.138Informatics
The introduction of Expert System technologies
to support Molecule Based Allergy Diagnostics
(MBAD) has also led to the introduction of new
concepts to the diagnostic approach.128 Indeed,
ISAC seems to be redundant to some extent: for
example, the number of profilins and LTPs
measured seem to be higher than needed.
Nevertheless, it has been recently observed that
a hierarchy of cross-reacting components can be
identified using large-scale MBAD assays.139 It was
shown that IgE reactivity of PR-10 proteins is
characterized by a hierarchical interrelationship:
Bet v 1 > Mal d 1 > Cor a 1.04 > Ara h 8 > Pru p
1 > Aln g 1 > Api g 1 > Act d 8 > Gly m 4. For this
reason, it is evident that having many cross-
reacting components indicates a lot more than
having only a few. Along this line, the rule is that if
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total number of components of a given family, the
patient can be considered sensitized to the whole
family of cross-reacting molecules.128 In addition,
the first sensitizer in the member of the family of
cross-reacting components can be identified as
the one with the highest IgE score. Other added
values can be derived from these rules: for
example, if a discrepancy is identified between the
results of SPT (or sIgE) of a certain extract of
allergen and the ISAC results (namely, a positive
SPT result with negative specific components
derived from that allergen), an expert system can
evaluate whether other cross-reacting components
(belonging to other allergen sources but cross-
reacting with components well known to be
detectable in the whole allergen) are also positive.
So, for example, if Ambrosia is positive in SPT but
Amb a 1 is negative, other cross reacting compo-
nents need evaluation. Profilins, PR-10, and CBP
are all well represented in Ambrosia but are not
present in ISAC. If at least one of these cross-
reacting components is positive, then a discrep-
ancy is not considered. On the contrary, if all the
possible cross-reacting components are negative,
a clear discrepancy is evident. By using this
approach, the number of apparent discrepancies
is reduced significanly. Another added value is
related to the capacity of an expert system to
evaluate the sum of the score of genuine inhalants
and the sum of the score of inhalant components
belonging to cross-reacting families. It has been
demostrated that patients sensitized to genuine
components are able to better respond to AIT than
people sensitized to cross-reacting compo-
nents.43,140 In addition, by the use of applying
cluster analysis techniques to data from
thousands of ISAC patients,141 it has been clearly
shown that there are five different clusters of
patients: Groups I and II (characterized by a
sensitization to a large fraction of genuine
components) are the only optimal targets for AIT,
while Groups III and IV have a worse expectation
of success. Group V relates to food allergies.
Starting from this evidence, a new era
characterized by the integration between artificial
intelligence tools and MBAD seems ready to
begin. Of note, many of these problems (in
particular discrepancies between the result of the
allergen extract and those of relevant
components) can be easily overcome by thestrategy used in ALEX, where both extracts and
single components are assayed in the same
allergen array.
A different approach that also works was used
by Prosperi et al. By using the techniques of ma-
chine learning, they studied how microarray results
can be applied to allergic diseases. A reasonable
discrimination ability for asthma, rhino-
conjunctivitis, wheeze and airway hyper-reactivity,
but not for eczema, starting from ISAC phenotyp-
ing, was observed142Interpretation of multiplexed in vitro allergy assays.
The interpretation of the results of a 112-
allergen assay, and even more a 282 allergen
assay, may be challenging, even for the experi-
enced and trained allergen-array user. Some
points should be carefully considered.
 Detection of sIgE is indicative of a sensitization,
and not of an allergy. Thus, a positive sIgE
response in the absence of a history of allergic
symptoms or a negative provocation should be
referred to as clinically irrelevant.143
 Clear differences have been described144
between allergen extracts and molecular
components (revised in Table 13). Sometimes
these discrepancies are quantitative, and sIgE
levels to the allergen extract are lower than for
the individual allergens when components are
in low abundance in the extract. In cases when
sIgE to allergen extract are positive but its
genuine components are negative, sensitization
to minor allergenic molecules or CCD
determinants responsible for cross-reactivity
should be ruled out. Of note, the recent sug-
gestion to introduce an inhibitor of CCD in the
sample diluent37 in order to reduce the signal
related to reactivity to CCD is routinely used in
the novel allergen array ALEX.127 This seems to
be particularly relevant when highly purified
components derived from natural extracts —
and, for this reason, characterized by the
presence of a post translational glycosylation —
are used. For example, in ImmunoCAP ISAC,
Walnut nJug r 2, Bermuda grass nCyn d 1,
Timothy grass nPhl p 4, Japanese cedar nCry j
1, Arizona cypress nCup a 1, and Plane nPla a
2 may be positive for their content of glycidic
chains This point was also noted in a AIT
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follow before administering AIT for pollens in
Mediterranean regions.
 This introduces another relevant point, repre-
sented by geographical differences in sensitiza-
tion. For example, Ole e 1 would be a marker of
genuine sensitization to olive pollen in the South
Spain but a marker of genuine sensitization to
ash tree in Northern France. An example of a
geographic distribution of sensitization has been
recently published145
 Differences in high or low risk markers and
component combinations create differences in
the interpretation of risk phenotypes. Generally,
allergens resistant to heat and digestion, like
seed-storage proteins or lipid transfer proteins,
often trigger more severe allergic reactions and
have been proposed as markers for severe re-
actions. Again, the specific relevance of each of
these markers of severity will vary according to
localmolecular profiles (e.g. in USA andNorthern
Europe Ara h 2 is the best predictive marker for
severe reactions to peanut, while in the Mediter-
ranean area it is Ara h 9). On the other hand, Bet v-
1 homologues and profilins are labile allergens,
which typically induce local symptoms such as
oral allergy syndrome (OAS) and have been pro-
posed as markers of mild reactions.
 However, the clinician needs to be aware that
there may be exceptions to this rule in situations
when large quantities of allergens are
consumed, cofactors are associated, or in re-
gions with large quantities of pollen exposure.
Examples of this are severe anaphylactic re-
actions reported in patients mono-sensitized to
Bet v1 homologues when drinking apple juice
after performing exercise,146 or severe reactions
in patients mono-sensitized to profilin in areas
with over-exposure to grass pollen.147 In
addition to considering the individual markers
of severe allergic reactions, component
combinations can define phenotypes with
different clinical expression. It has been
recently reported that, in an Italian cohort,
sensitization to more than 5 nsLTPs out of the 8
present in ImmunoCAP ISAC  is related to a
higher incidence of food-induced systemic re-
actions, while co-sensitization to PR-10 or profilin
pan-allergens is associated with mildersymptoms.148 According to this, the assessment
of IgE sensitization to the three key allergens —
Bet v 1 homologues, LTPs and profilins — is of
paramount importance for the interpretation of
molecular diagnosis to fruits and vegetables,
especially in the Mediterranean area.149
 An advantage of multiplex analysis is also one of
its main pitfalls: the generation of an extensive
IgE sensitization profile, detecting IgE to unex-
pected allergens, which may sometimes induce
confusion in the clinician if there is no suggestive
pre-test clinical history. That is often the case in
insect venom allergy. Due to the high prevalence
of insect venom sensitization in approximately
25% of the population, nonspecific screening
would generate an abundance of clinically irrel-
evant results and mainly serve to unsettle pa-
tients and their physicians.150 No
recommendations are currently available on
how to effectively manage these cases,137 but
it seems reasonable to act in the same way as
with other clinically irrelevant sensitizations to
food or respiratory allergens that don't need
any intervention other than to follow the
patient to detect possible future reactions. On
the other hand, the detection of silent
sensitivities may give the allergist the chance to
investigate other hypersensitivities and to alert
the patient towards possible risks.151 In the
case of sensitization to allergens responsible
for food-pollen cross-reactive syndromes, the
clinician should re-interrogate the patient for
symptoms upon consumption of foods contain-
ing those allergens. However, sensitization itself
should not drive avoidance measures.152 It is
important to state that according to current
guidelines the indication of an elimination diet
should be recommended only if food allergy
due to cross-reactions is based on a clear his-
tory or on a clinical observation after oral prov-
ocation tests.153
 A further approach can be based on some sim-
ple rules from proteomics. It has been defined
that a cross-reaction may occur if the homology
between two or more molecular allergens is
>70%.This is a very simple rule that can be easily
verified by comparing the sequences of two
components which are suspected to be related.
It is evident that components belonging to the
same family (such as PR-10) are highly
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h 8 (Peanut), Aspa o 17kD (Asparagus officinalis),
Cas s 1 (Chestnut), Fag s 1 (Fagus sylvatica), Fic c
1 (Ficus carica), Jug r 5 (Walnut), Mor a 1 (White
Mulberry), Ost c 1 (Ostrya carpinifolia), Rub i 1
(Rubus idaeus), Sol a l 4 (Tomato), Tri fg 4
(Trigonella foenum-graecum), Vig r 1 (Vigna
radiata), etc. In these cases, the presence of
cross reactions always should be considered.
Other situations can be different. For example, in
the presence of a weak positivity to Ambrosia a.,
the presence of a strong IgE reaction to Arte-
misia v. should be verified, because of the
presence of a Amb a 1 like protein in Artemsia.
Finally, a well known exception is represented by
LTP from Par j 2, that when compared with Pru p
3 (a prototypic nsLTP) shares a 26% identity and
a 52% positivity, while Pru p 3 compared with
Mal d 3 (another nsLTP) has an identity ¼ 77%
and positivity ¼ 83%, clearly justifying the pres-
ence of a cross reaction.
Cellular assays: basophil activation test
Cellular assays assess selected and defined
functions of effector cells within the allergic
cascade, and therefore play an increasing role
within in vitro allergy diagnostic tests. This is
particularly true in case of equivocal and/or
negative results obtained with other in vitro and
in vivo tests, and in case of discrepant results. In
this context, the basophil activation test (BAT) has
gained increasing interest within the scientific
community and supplanted traditional histamine
release assays.154
General aspects
Basophils, like mast cells, are recognized as
important effector cells in immediate hypersensi-
tivity responses. Basophils express the high-affinity
IgE receptor (FcεRI), and thus they carry specific
IgE (sIgE) antibodies on their surface and degra-
nulate when the allergen cross-links these sIgE/
FcεRI complexes. This degranulation of basophils
can be detected and quantified by flow cytometry
techniques.155 Since mast cells, a tissue-resident
cell also expressing FcεRI, are not accessible for
in vitro diagnostic tests, the basophil represents a
unique alternative to study sIgE/FcεRI-dependent
degranulation. Moreover, comparative analyses
between mast cells and basophils might benefitstudies of sIgE/FcεRI-independent effector cell
activation, such as by off-target occupancy of the
MRGPRX2 receptors,156 as basophils, unlike
cutaneous mast cells, barely express this
receptor.157
Over the last two decades several important
advances have been achieved, announcing the
BAT as an increasingly attractive in vitro diagnostic
tool, to be applied in selected contexts. However,
some methodological aspects need to be taken
into consideration in order to interpret the data
correctly:
o The BAT is a flow-cytometric based assay:
therefore, the investigator must be trained in
flow-cytometric techniques, and proper equip-
ment is required. The principles of the BAT and
HistaFlow technique, that studies intracellular
histamine content, are summarized
elsewhere.155,158,159
o There are several surface-marker combinations,
which allow the correct identification of baso-
phils. They include the combinations CCR3þ/
CD3-, or CD123þ/HLA-DR-, or IgEþ/CD203cþ.
The only lineage-specific basophil marker is
CD203c. The precise identification of the popu-
lation of basophils is a prerequisite for a valid
interpretation of test results.
o In a second step, the appearance and/or up-
regulation of the desired activation/degranula-
tion marker is investigated. CD63 or (lysosomal-
associated membrane protein [LAMP-3]), is a
degranulation marker that appears during
compounded degranulation of the cell. CD203c,
or ectonucleotide pyrophosphatase/phospho-
diesterase 3 (ENPP-3), is not only a lineage
specific marker of basophils, but it also serves as
an activation marker. In the resting basophil, the
expression of CD203c is low, and activation re-
sults in a rapid and marked increase in CD203c.
Other activation/degranulation markers can also
be used, amongst them analysis of the intracel-
lular histamine content using an enzyme affinity
method (HistaFlow).159 Fig. 1 illustrates the
principle of the BAT/HistaFlow.
o Although commercial basophil activation assays
are available, these are rarely thoroughly vali-
dated and require additional investigation
before they can enter mainstream application.
Fig. 1 The principle of the BAT/HistaFlow
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techniques and interpretation of outcome values
and results are still lacking. This is particularly
important in the definition of decision cut-off
values. Until international agreement and stan-
dardization has been achieved, each laboratory
should establish its own cut-off values. The best
current available definition of a positive test
result is based on the frequency of activated
basophils following stimulation. For proteina-
ceous allergens, a test result of at least 15%
activated basophils is generally considered as a
reliable cut-off value, eventually together with a
stimulation index (compared to the negative
control) of at least 2. For drugs and small
chemical substances, which are known to be less
potent stimulators, lower decision thresholds
frequently apply. Anyhow, it is recommended to
abandon arbitrarily chosen decision thresholds.
As a matter of fact, broad dose-findingexperiments, spanning different stimulation
concentrations and receiver operating charac-
teristic (ROC) analysis are required to calculate
allergen-specific cut-offs. Obviously, viability
and cytotoxicity studies are mandatory to
exclude false-negative results.
o Pre-analytical considerations are of utmost
importance, in order to obtain valid test results.
In this regard, the BAT is best performed not
later than 6–12 months after clinical reaction.
However, BAT can stay positive over years, even
for drugs.
o It has been demonstrated that antihistamines do
NOT influence the outcome in BAT.160
Therefore, unlike for skin and provocation tests,
these drugs should not be discontinued.
o A key problem still remains, the so-called
“anergic”, that is, non-responders in the BAT.
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phils. A paper published in 2017 showed how
inactivation of basophils (“basophil anergy”)
seems to be associated with a down regulation
of basophil Syk and an apparent reduction in the
incidence of allergic rhinitis.161 For this, anti-IgE
can be used as a positive control in BAT to
identify non-responders.
o Of great advantage, particularly in comparison
to in vitro IgE antibody diagnostic tests, is the
fact that the BAT assesses IgE-dependent as well
as IgE-independent mechanisms. Activation of
the basophils is not only obtained through IgE-
dependent signal transduction pathways, but it
can also be the consequence of a non-IgE
mediated reaction. In addition, as already
exemplified, comparisons between mast cell
and basophil activation can benefit identification
and investigation of alternative activation path-
ways, such as occupancy of the MRGPRX-
receptor.BAT in food allergy
The application of BAT in food allergy has to be
seen in the overall context of molecular di-
agnostics.162 A major issue that is not addressed
here is the allergen source. BAT might
significantly differ according to the variety
employed (e.g. it has been proven for
peanut).163 Nevertheless, BAT can benefit
diagnosis in difficult cases despite not very
reliable in plant-derived food allergy.
Cow's milk allergy is one of the most common
food allergies in early childhood. In a study by
Rubio et al.164 several diagnostic methods were
compared in order to assess the diagnostic value
for each. The comparison of skin test, anti-cow's
milk IgE antibody measurement, and BAT
revealed that BAT yielded the highest specificity
(90%) and sensitivity (91%), the highest positive
predictive value with 81%, and the highest
negative predictive value with 96%.
In another study165 food allergy was assessed in
a cohort of 120 patients with suspected irritable
bowel disease. The presence of food allergy was
established by double-blind, placebo-controlled
food challenges. The comparison of specific IgE
measurements and BAT revealed a significantlyhigher diagnostic accuracy for the BAT (sensitivity
86%, specificity 88%).
These data have been confirmed in a study,
where basophil activation was statistically
correlated with double-blind placebo-controlled
food challenge (DBPCFC) outcomes and
severity scores, and compared to SPT and
serum sIgE.166
Furthermore, the BAT assay has been investi-
gated and correlated with the degree of cow's milk
tolerance in 132 subjects divided into 3 groups:
baked-milk-reactive, baked-milk-tolerant or
“outgrown milk allergy”, based on the oral food
challenge outcomes. BAT showed a significantly
higher diagnostic accuracy compared to specific-
IgE measurements (sensitivity 86%, specificity
88%). The basophil reactivity was significantly
higher in baked-milk-reactive patients rather than
in baked-milk-tolerant subjects (P < 0.01), and
statistically higher in baked-milk-tolerant in-
dividuals than in those who have overcome their
allergy (P < 0.05).167
Similar results were obtained with other foods,
such as egg and tree nut allergens. A study group
compared the basophil allergen threshold sensi-
tivity (CD-sens) to peanut allergen-specific IgE
antibody levels in relation to the DBPCFC
outcome. BATs were performed with both peanut
extract and purified rAra h 2: they showed positive
results in 92% of the samples, in agreement with a
positive DBPC food challenge. Negative outcome
in CD-sens was associated with negative results in
DBPCFC.168–170
Although these data must be confirmed by
additional studies, this initial set of results indicates
that at least for certain food allergens and in
certain populations, the BAT plays a significant role
in establishing the diagnosis.
BAT in drug allergy
Needless to say, one of the major applications
of BAT is immediate drug hypersensitivity, as (in
contrast to food allergy) there is no need for diffi-
cult extract preparation, and other in vitro tests are
frequently lacking and skin tests still associated
with considerable uncertainty. Moreover, it has
been shown that drug challenges based on skin
testing are not absolutely predictive to give a
green light for safe subsequent re-exposure.171
Volume 13, No. 2, February 2020 33To date, as reviewed in Mangodt et al and Ebo
et al,172,173 BAT has mainly been studied in
immediate hypersensitivity drug reactions due to
neuromuscular blocking agents (NMBAs),
antibiotics (b-lactams and fluoroquinolones), and
iodinated contrast media (ICM). BAT sensitivity
generally ranges between 50% and 60%, and
specificity is 80%, except for fluoroquinolones
where lower sensitivity of the BAT probably
reflects an alternative mechanistic endotype.157
Presently, BAT appears to be the only reliable
technique to diagnose IgE-mediated opiate
hypersensitivity.174,175BAT in venom allergy
The potential and limitations of BAT in the
diagnosis of venom allergy should be viewed in
the context of recent developments in molecular
diagnostic tests that have greatly improved diag-
nosis in difficult cases,176,177 mainly patients
demonstrating double positive sIgE results and at
risk for inappropriate venom immunotherapy. In
addition, BAT can benefit diagnosis in patients
with negative results. BAT can be performed
using native extracts but also with recombinant
venom proteins that are increasingly
characterized and cloned. Another application of
BAT in venom allergy is monitoring of treatment.
From these follow-up studies it emerges that it is
important to distinguish between basophil sensi-
tivity and reactivity, as the effect of venom immu-
notherapy on basophils is mainly seen when the
cells are stimulated with suboptimal
concentrations.178ALLERGEN PROVOCATION TEST
Allergen extracts can be applied to the
conjunctival, bronchial or nasal mucosa in order to
provoke symptoms and to clinically demonstrate
relevance of IgE-mediated sensitization (as identi-
fied by skin-testing or by in vitro parameters) in
patients with allergic rhinoconjunctivitis and/or
allergic asthma.179,180 Allergen provocation tests
are useful in confirming the diagnosis of
underlying allergic disease, if by clinical history,
skin tests and specific IgE determinations are not
conclusive. There is, however, the potential for asystemic reaction, especially with inhalation
challenges.
As such, these challenges should be standard-
ized to some extent, in order to control environ-
mental conditions (e.g., temperature, humidity),
and can be performed repeatedly in selected in-
dividual patients. However, an international stan-
dardization of protocols for these provocation tests
has been identified as an important unmet
need,180 which has been followed by the
European Academy of Allergy and Clinical
Immunology (EAACI) in a Position Paper on
“standardization of nasal allergen challenges“181
and “conjunctival allergen provocation test:
guidelines for daily practice“.182 In the “Guideline
on the clinical development of products for
specific immunotherapy for the treatment of
allergic diseases” the European Medicines
Agency (EMA) has stated that in phase II “dose
finding trials on allergen immunotherapy (AIT),
provocation tests may be used as primary
endpoints”. Besides that, they can be used in
pharmacodynamic trials or in Phase III (pivotal)
trials to support proof of efficacy.183
Allergen Exposure Chambers (AECs) have the
advantage of mimicking real-life allergen expo-
sures by challenging not only single target organs
but the entire patient. In particular the conjunctival
mucosa as well as upper and lower airways are
exposed simultaneously. The number of technically
validated AEC facilities has increased during the
past two decades, and they are frequently used in
clinical trials.183,184 Through the 2016 revision of
the “Allergic Rhinitis: Developing Drug Products
for Treatment Guidance for Industry“ document,
the Center for Drug Evaluation and Research
(CDER) of the U.S. Department of Health and
Human Services Food and Drug Administration
(FDA) underlines the role of AECs as useful tools
in clinically assessing allergic rhinitis.185 In line
with this, the EMA acknowledges AEC facilities as
a promising tool for the evaluation of efficacy in
AIT but calls for further clinical validation.183
Therefore, a published EAACI Position paper
overviewed current concepts and unmet needs in
AECs aimed to enhance progress towards a
broader use of these facilities in the future.186
Taken together, allergen challenge tests can be
ideally used to demonstrate the clinical relevance
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diagnostic methods for allergenic diseases. How-
ever, a thorough standardization of these proced-
ures as well as further validation is needed. Even
though the number of AECs world-wide is still
limited, these facilities may play an important role
as diagnostic and therapy-monitoring tools in the
future.185SPECIAL CASES IN ALLERGY DIAGNOSIS
IgE testing in drug allergy
IgE-mediated drug allergy accounts for only a
limited portion of immune-mediated adverse drug
reactions. Even when the clinical picture is consis-
tent with an immediate drug reaction suggesting
the involvement of IgE, the sensitivity of skin prick/
intradermal testing and serum specific IgE assays
remains low for many drug groups. The reasons
include the following:187
 Drugs seldom are complete antigens, but
frequently act as haptens which require protein
binding to become a complete antigen, in this
case an “allergen” with IgE-binding capability.
 Some drugs trigger allergic reactions through
their metabolites.
 Some immediate reactions may not be IgE-
mediated.
All these factors contribute to challenges in
consistently reproducing the pathogenic mecha-
nism(s) involved in allergic drug reactions.188
Taking into account these limitations, skin
testing with suspected drugs is still a widely used
first-line procedure to assess the possibility of a
drug allergy. One of the major problems is that
concentration ranges allowing for an acceptable
sensitivity but lacking an irritant effect have only
been reported for a limited number of drugs, such
as b-lactams, neuromuscular blocking agents
(NMBAs), platinum salts, iodinated contrast media,
and heparins (see Table 8). Others have been
published only as isolated case reports or small
case series.
The positive and negative predictive value of
skin testing with drugs or specific-IgE determina-
tion varies, according to each specific drug, to the
selection criteria of the patients to be tested(likelihood of allergic reaction) and to the time
elapsed between the last reaction and testing,
since the sensitivity of the latter decreases pro-
gressively with time.189–191Skin testing for drug allergy
A variety of factors need consideration for
performing and interpreting drug allergy skin
testing. Positive and negative control tests should
be performed simultaneously, usually with hista-
mine and normal saline respectively. Skin testing
with drugs should be performed in a setting with
sufficient resources to facilitate management of
systemic reactions. Patients may sign an informed
consent document, which might be mandatory in
some countries. Tests should be started by SPTs,
and if these are negative, followed by IDT starting
with the lowest concentrations, until a positive
reaction is obtained or until the maximum con-
centration is reached. Whenever the test is per-
formed with a drug for which the appropriate
concentrations have not been validated, it may be
necessary to test control subjects, such as the
physician and clinical staff, to rule out non-specific
responses.
In b-lactam skin testing, it is recommended to
use the major and minor determinants of benzyl-
penicillin, as well as the culprit drug and possibly
other b-lactams, to ascertain any cross-reac-
tivity.189 Benzylpenicilloyl-poly-L-lysine (PPL, Pre-
pen, AllerQuest LLC, Plainville, CT, USA) and
benzylpenicilloyl-octa-L-lysine (BP-OL, DAP, Dia-
ter, Leganes, Spain) are the major determinants in
use today, while the minor determinants are ben-
zylpenicillin and sodium benzylpenilloate (DAP).
However, they are not commercially available in all
countries. The sensitivity of skin testing with b-lac-
tams differs among studies; it can reach 80% in
immediate reactions (i.e., occurring within 1 hour
of the last drug administration).187 For most
antibiotics other than b-lactams, the value of skin
tests appears to be less clear or not yet
validated. SPT and IDT with undiluted
intravenous quinolones are irritative. Higher
dilutions have to be used in order to avoid these
irritating results. Recommended highest non-
irritative dilutions in the literature vary greatly. In
any case, the sensitivity of skin testing with quino-
lones appears to be low and recommendations on
concentrations are currently not possible. In
Volume 13, No. 2, February 2020 35immediate hypersensitivity reactions to macro-
lides, positive skin tests appear to be rare. In some
studies, undiluted concentrations of i.v. macrolides
have been reported to be irritating in the SPT.
Table 17 summarizes the concentrations
recommended for the drugs most frequently
involved in IgE-mediated reactions.
In pediatric patients, the definitive diagnosis of
b-lactam and non b-lactam antibiotics (NBLAs) hy-
persensitivity frequently depends on drug provo-
cation tests. Studies including children showedDrug
b-lactam antibiotics
Amoxicillin
Ampicillin
Penicillin G 1
Cephalosporins 2
Aztreonam
Imipenem/cilastin 0.5
Meropenem
Neuromuscular blocking agents (NMBAs)
Atracurium
Cisacurium
Mivacurium
Rocuronium
Vecuronium
Pancuronium
Suxamethonium
Platinum salts
Carboplatin
Oxaliplatin
Cisplatin
Iodinated contrast media Un
Heparins Un
Pyrazolones (Metamizol) and other NSAIDs Un
Table 17. Highest drug concentrations recommended for skin testing.
administered drugs - an ENDA/EAACI Drug Allergy Interest Group position papethat only 7.8–36% of suspected hypersensitivity
(both immediate and delayed) to NBLAs could be
confirmed by skin and/or provocation tests, hence
the need of a common guideline on a standard-
ized diagnostic approach in the pediatric
population.192
For neuromuscular blocking agents (NMBAs),
skin tests are generally considered to have a high
sensitivity. Cross-reactivity is reported with NMBAs
in up to 60–70% of cases,193 even if it is possible
that different results are observed.SPT IDT Reference
189,190
20 mg/ml 20 mg/ml
20 mg/ml 20 mg/ml 190
0,000 UI/ml 10,000 UI/ml
–20 mg/ml 20 mg/ml230
2 mg/ml 2 mg/ml
mg/ml each 0.5 mg/ml each 190
1 mg/ml 1 mg/ml
190
1 mg/ml 0.01 mg/ml
2 mg/ml 0.02 mg/ml
0.2 mg/ml 0.002 mg/ml
10 mg/ml 0.05 mg/ml
4 mg/ml 0.4 mg/ml
2 mg/ml 0.2 mg/ml
10 mg/ml 0.1 mg/ml
190
10 mg/ml 1 mg/ml
1 mg/ml 0.1 mg/ml
1 mg/ml 0.1 mg/ml
diluted 1/10 in normal saline 190
diluted 1/10 in normal saline
diluted 0.1 mg/ml
*Adapted from K. Brockow et al.: Skin test concentrations for systemically
r.231
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http://doi.org/10.1016/j.waojou.2019.100080If a skin test with the NMBA to which the patient
was exposed is positive, the remaining available
NMBAs should be tested, in order to rule out
cross-sensitizations and identify safe alternatives.
NMBAs can induce a non-specific direct histamine
release in the skin, increasing the risk of false
positive tests, especially in intradermal testing.194
There remains the possibility of low specificity
based upon exposure and sensitization to
common products (cosmetics and cough
medicine) which lead to false positive results.195
Hagau and colleagues demonstrated that sub-
jects with a history of antibiotic hypersensitivity
reactions seem to have an increased incidence of
positive skin tests for NMBAs, in particular atracu-
rium (P ¼ 0.02). These data suggest that there is a
subset of patients that might be at higher risk for
developing intraoperative anaphylaxis after un-
dergoing general anesthesia, compared to the
general population.196 With regard to platinum
salts (carboplatin, oxaliplatin, and cisplatin), there
is sufficient information to recommend the use of
undiluted drugs for SPT and a tenfold dilution for
IDT.197
Skin testing with iodinated contrast media (ICM)
is suggested in patients who have previously
experienced contrast-related reactions. On the
contrary, there are no indications in non-ICM-
exposed and/or non-previous-reactors for testing
as the predictability of these skin tests has not
been confirmed. In those with positive reactions,
testing a panel of different compounds is recom-
mended to detect any cross-reactivity. SPT should
be performed using undiluted solutions. For IDT,
preparations should be used in a 1:10 dilution, as
undiluted contrast media may be irritating.198
Sese et al. published their experience with a low-
dose intravenous provocation test with ICM that,
added to skin tests, seem to have a NPV of 80% inDrug Techniques
NMBA RIA/RAST/CAP FEIA
b-lactams RAST/CAP FEIA/Sephar
Quinolones Sepharose-RIA
Propyphenazone ELISA
Table 18. Summary of IgE testing for drug allergy in different drug gro
immunoassay; RAST radioallergosorbent test; RIA, radioimmunoassay; ND, not da cohort of 37 patients with suspected hypersen-
sitivity reactions to ICM. Only one subject experi-
enced a mild adverse reaction. Further studies
however are needed to confirm the safety and
predictive value of this procedure.198
Heparin preparations should be used in a 1:10
dilution for intradermal tests. Immediate-type in-
tradermal-test positivity may be observed in up to
10% using this dilution. Lower concentrations
decrease the sensitivity of these tests.199
For non-steroidal anti-inflammatory drugs
(NSAIDs), the sensitivity of skin testing is low except
for pyrazolones.200 In fact, the vast majority of
immediate hypersensitivity reactions (e.g.,
urticaria, bronchospasm, and anaphylaxis) to
NSAIDs, excluding pyrazolones, are not due to an
IgE-mediated mechanism, but are related to an
aberrant arachidonic acid metabolism. In immedi-
ate hypersensitivity reactions to pyrazolones, posi-
tive skin tests may occur in up to 40% of patients.
Nevertheless, some cases have been published for
NSAIDs other than pyrazolones, in which skin tests
have rendered positive results (Table 17). Although
immediate corticosteroid allergy is infrequent, skin
tests may be useful for diagnosis. However, skin
testing or sIgE is not generally recognized of value
for ICM or NSAIDs allergies in the USA.In vitro testing for drug-specific IgE
The possibility of proving the existence of serum
specific IgE to the suspected drug in an allergic
reaction would make it possible to avoid per-
forming in vivo tests, reducing the possibility of
unwanted adverse reactions. Nevertheless, only a
few IgE assays are commercially available for drug
allergy diagnosis, with variable predictive values.
In some cases, individual laboratory assays, such as
ELISA or FEIA, are used. Table 18 summarizes theSensitivity Specificity
47–97% 91–100%
ose-RIA 0–87% 67–97%
32–55% 100%, ND
58% ND
ups ELISA, enzyme-linked immunosorbent assay; FEIA, fluorometric enzyme
one. Adapted from.232
Volume 13, No. 2, February 2020 37value of IgE testing for drug allergy for the most
relevant studied drug groups. However, there is
an honest difference of opinion regarding the
interpretation of these results between US and
European allergists.
BAT for drug allergy
This topic is discussed in the BAT chapter of this
article.
IgE assays for occupational allergens
Occupational allergen sources may be materials
that a large part of the general population is
exposed to, but only occupational settings provide
sufficiently high, prolonged and relevant exposure
to cause sensitization and, eventually, allergic dis-
eases. Two examples are flour dust and industrial
detergent enzymes where the majority of reported
cases come from industries and bakeries where
large amounts of these source materials are
handled.
IgE-testing plays a particularly important role in
occupational allergy because of the relatively rare
occurrence of the individual allergenic sources,
and thus a correspondingly low number of stan-
dardized extracts for skin testing.201 Even locally
or ad hoc produced skin test extracts may suffer
from problems of toxicity that may limit the use
of skin test as a diagnostic procedure. The lack of
pre-produced extracts, however, may also be a
problem for IgE-testing in settings where it is not
possible to develop new assays based on an
extract of the occupational material that is sus-
pected of causing allergy. For this reason, the
basophil histamine release assay or BAT may be a
helpful technique, since it is possible to make an
extract of the suspected material and use it for
challenging the basophils. It is pertinent though,
that the proper controls (no activation of basophils
from healthy persons, no interference with the
assay in general) are carried out.
The range of occupations in which IgE-mediated
diseases have been reported is vast and varied,
and it is important to realize that Occupational
Allergy is a field with not only protein allergens but
also small molecules, examples of which are given
below. In many cases the specific allergen(s) from
an occupational exposure have been identified,
but there are also cases where a whole extract ofthe allergen source is the only available diagnostic
tool. An interesting example in this respect is latex,
which has been reported as an important allergen
for health care workers,202,203 in which an
outbreak of an allergy "epidemic" was observed
in the years following the increased utilization of
rubber gloves in the 1980s. Latex, the raw
product of natural rubber, contains more than
200 polypeptides, and as of today 14 proteins,
Hev b 1 to Hev b 14 have been given an IUIS
nomenclature designation, with many isoforms
and variants within these. Additional latex
proteins have been isolated but have not
received a designated allergen name. Health
care workers seem to be particularly frequently
sensitized to Hev b 5 and b 6.02, but many other
sensitizing allergens have been reported.203 The
ideal diagnostic work-up, if the reagents are
available, is for a two-step process, where the
sensitization to the whole extract is first demon-
strated, after which the sensitization to individual
allergens can be analyzed. While the sensitization
to the whole extract is of relevance for the occu-
pational exposure (since the patient is of course
exposed to the whole product), the elucidation of
the sensitization to individual allergenic molecules
may be of relevance in advising the patient about
cross-reactivities that may be experienced outside
of work. Latex sensitization to Hev b 6.02 may
confer cross-reactivity to endochitinases contained
in avocado, chestnut, banana, and sweet pepper,
whereas sensitization to Hev b 5 may cause cross-
reactivity to kiwi fruit. Another aspect of cross-
reactivity that should be considered is the possi-
bility that the patient may be sensitized to pollens
which may cause recognition of cross-reacting
carbohydrate determinants (CCD)204 or profilins
(Hev b 8 in latex, Phl p 12 in Timothy grass).205
A very important area of occupational allergy
occurs with exposure to proteins in the handling of
food whether it is in the industrial, workshop-
based (bakeries, butchers) or catering sector. The
most important exposure route is likely to be via
inhalation of dust or aerosols created during the
manufacturing process, but also absorption via the
skin should be considered. A list of the foods that
have been reported to act as occupational aller-
gens in causing asthma include food from both the
plant kingdom (cereals, seeds, whole plants, veg-
etables, fruits, spices, teas) and the animal
38 Ansotegui et al. World Allergy Organization Journal (2020) 13:100080
http://doi.org/10.1016/j.waojou.2019.100080kingdom (seafood and fish, meats from mammals
and birds, milk and eggs).206,207 This list was
updated in 2014.207
Probably the best-described occupational al-
lergy to food is baker's asthma where the patient
may be sensitized to the flour but also to additives
in the form of enzymes (fungal alpha-amylase
added to improve the leavening of the dough) or
insect pests in the form of cockroaches that may be
contaminants. IgE-reactivity to wheat flour may
serve as an interesting lesson regarding occupa-
tional versus non-occupational reactivity. Wheat
IgE-mediated allergy manifests itself as food al-
lergy and as occupational inhalant allergy (baker's
asthma),208 and identical allergens seem to be
responsible in both allergies, although their
relative importance differs.209,210 Nevertheless,
healthy patients may also display positive skin
test or specific IgE towards wheat, due to the
cross-reactivity between grass pollen and cereals
which may have an impact on the specificity of the
diagnostic tests.74,211 This was confirmed in a
study, showing up to 35% positivity against wheat
for both skin prick tests and sIgE tests, when
testing grass pollen allergic subjects that
tolerated eating wheat and other cereals and
without a history of baker's asthma.212 Thus also
for occupational allergens, specificity remains an
important issue.
In addition to the raw products involved, food
additives and contaminants including insects,
fungi and parasites should also be considered. To
compensate for a low content of natural amylases,
bioindustrially produced a-amylases are added to
wheat flour to improve the leavening of the dough.
One such a-amylase is derived from Aspergillus
oryzae and formulated as the product Fungamyl,
which has been used as an additive to flour for
more than 40 years. This preparation of a-amylase
complies with the FAO/WHO JECFA recom-
mended specifications for food grade enzymes,213
and it is generally considered as safe for human
ingestion. Occupational exposure to enzyme
dust, however, may cause type I allergic
sensitization and allergic symptoms like asthma,
rhinitis, and urticaria may be elicited on
subsequent exposure.214 Preparations of a-
amylase derived from Aspergillus oryzae,
including Fungamyl, in several cases, have
been reported to cause sensitization of workersin enzyme production plants,215 the
pharmaceutical industry,216 and bakeries.217
Other enzymes such as those used in the
detergent industry have also been known to cause
problems. The initial proteases used in detergents
were produced by fermentation of Bacillus subtilis,
and thus called subtilisins. Soon after the intro-
duction of a subtilisin in detergent products, se-
vere IgE-mediated asthma reactions appeared
among workers in detergent factories.218 Strict
exposure control programs reduced the
exposures to low levels (15 ng/m3 range), which
reduced sensitization and prevented the onset of
allergic symptoms.219 Large scale studies of
sensitization and allergic symptoms suggest that
sensitization comes first, and only in some cases
leads to development of symptoms. It has also
been suggested that not only enzymes, but also
whole microorganisms used in the food and feed
industries may cause an allergy risk. Cleaning
workers having asthma and/or rhinitis should also
be evaluated, even though only a minority could
actually be sensitized.
Other exposures to high molecular weight al-
lergens may be seen in occupations with live ani-
mals such as farms or experimental animal facilities
(where rodent urinary proteins seem to be a strong
sensitizing allergen) and with plants from the
farming and the gardening industry.220
Finally, occupational allergies may develop to
small organic molecules, that are either complete
allergens with a symmetric structure such as chlor-
hexidine221 or incomplete allergens that act as
haptens by binding to carrier molecules, which are
generally human proteins.222 Examples are
ethylene oxide, formaldehyde, isocyanates, and
phthallic anhydride that are used for the
production of polyurethane.223 The isocyanate
group compromise different chemical species, and
there seems to be a certain cross-reactivity.224
Notably, in these cases, skin test or specific IgE in
serum are not useful tools for diagnosis.225
In conclusion, IgE-based diagnostic methods for
occupational allergies are not, in principle,
different from other types of allergies. The large
number of different allergenic sources for which
occupational sensitizations have been reported,
however, has made the research area more
extensive, and for many occupations the specific
Test Description Scientific evidence References
Specific IgG
antibodies
Food specific IgG or IgG4 panels are available as
diagnostic tool for food allergy (NOTE: healthy
subjects can produce specific IgG and IgG4 to
commonly eaten foods without being allergic).
The titer of specific IgG-antibodies does not
correlate with oral food challenges. In children with
proven milk allergy (positive oral challenge) no
increase in specific IgG was detected. There is no
evidence that IgG subclasses are a reliable
diagnostic tool. Seventy-three patients were
challenged in a double-blind manner to the IgG4
positive food, with no adverse reactions reported.
233–235
Cytotoxic test This is an in vitro test in which food allergens (up to
180) are put into contact with whole blood. Any
change in leukocytes' shape indicates a positive
reaction.
In controlled conditions the reproducibility and
diagnostic efficiency were largely insufficient.
236,237
Hair analysis Nutritional deficiencies, detectable in hair (e.g., zinc,
magnesium) are due to food allergy/intolerance.
Nine allergic patients to fish (positive challenge) and
9 healthy controls underwent the test. The test did
not recognize allergic patients, and additional
allergies were found without clinical significance.
Hair samples of two teenagers were tested in 13
different laboratories, which reported different
results.
238,239
Iridology Anatomical/morphological changes in the iris may
suggest systemic diseases.
A systematic review on iridology concluded that this
test as a diagnostic tool is not supported by scientific
evidence.
240
Kinesiology The patient holds a vial with a specific food in one
hand, while the examiner tests the muscular strength
of the opposite arm by applying a light pressure.
Food allergy/intolerance is indicated by a decreased
muscular contraction when the offending substance
is held.
According to two controlled studies the scientific
evidence suggests that this diagnostic modality is
not validated, and kinesiology as a diagnostic tool is
no better than random guessing.
241,242
Electrodermal
testing
The patient is placed in a circuit where a
galvanometer measures skin conductance. Vials with
food extract are sequentially inserted into the circuit.
A positive response consists of a drop in
conductance.
According to two double-blind placebo-controlled
studies this method failed to distinguish between
allergic and non-allergic patients, and between
positive and negative tests. Poor reproducibility was
always reported.
243,244
Table 19. Unproven diagnostic approaches
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different allergy "epidemics" such as latex, indus-
trial enzymes, and proteins from experimental an-
imals have gradually been contained even though
new sensitizations still occur. On the other hand
new processes, and particularly those that involve
handling of, and exposure to, proteins, may also
create new and hitherto unknown exposures that
may cause new IgE-mediated allergies.Unproven diagnostic approaches
Food allergy is a frequent allergic disorder, as 6–
8% of children and 2–3% of adults are affected.
However, the public perception of food allergy/
intolerance is higher, as one out of three people
believes they are allergic or intolerant to one or
more foods. This perception is at least in part
based on the results of unproven diagnostic ap-
proaches (Table 19). Therefore these unreliable
diagnostic approaches may be costly for patients,
delaying appropriate diagnosis and therapy.CONCLUSION
For type I IgE-mediated allergic disease, skin
tests are still considered the first-line approach for
indicating the presence of allergen-specific IgE
antibodies on the surface of mast cells in the skin
of a sensitized patient. Skin testing is a simple and
generally safe method, reliable in skilled hands;
the results are reproducible when standardized
extracts are employed. As complementary or
alternative diagnostics tools, in vitro serum IgE
detection with the use of highly purified allergen
or recombinants, in singleplex or multiplex
manner, is an alternative diagnostic procedure.
Serum IgE testing entails no risk to the patient
other than a blood draw and is preferable if the
patient has an unstable or uncontrolled medical
condition, is at high risk of anaphylaxis, is taking
essential medication that interferes with testing, is
very young such that the procedure would be
unduly stressful, or has a skin condition that limits
available skin for testing. The development of
screening tests with multiple allergens or multiplex
tests that identify multiple specific-IgEs with a small
blood volume makes this testing more appealing
to very young children. However, food allergy
panels need to be adapted and improved in order
to be cost-effective and more specific.Furthermore, the development of cellular assays
such as the BAT may improve the diagnostic ac-
curacy of testing, particularly for food, venoms,
and drugs. However, BAT, standardized extracts,
component testing, multiplex testing, and micro-
arrays are only available for specific allergens,
thus, having limited clinical availability.
Great effort is now focused on the standardiza-
tion process, both for testing and production of
immunotherapy extracts. Standardization will
result in optimal, reproducible, accurate testing
that will improve patient outcomes and general
health care. Additional population studies are
necessary to verify if more specific testing, such as
component assays, are relevant before these as-
says can be recommended. The ultimate value of
allergy testing depends upon the pretest proba-
bility derived from history and physical examina-
tion that precedes the testing, as the clinical
judgment of the healthcare provider influences
greatly the predictive value of allergy testing. No
test can substitute for the importance of an
adequate assessment, and remote testing should
be discouraged to limit misdiagnosis.POSITION PAPER REVIEW AND
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